Archive for September, 2013

(CYTR) to Present at the Aegis Capital Corp. 2013 Healthcare Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A. Kriegsman and Vice President of Business Development David J. Haen will present at the Aegis Capital Corp. 2013 Healthcare Conference on Thursday, September 26 at 1:00 p.m. Pacific time (4:00 p.m. Eastern time). The conference is being held at the Wynn Las Vegas.

About the Aegis Capital Corp. 2013 Healthcare Conference

The Aegis Capital Corp. 2013 Healthcare Conference, being held September 25-September 28, will feature more than 45 companies within the healthcare space. Presenting companies will be showcased through a combination of company presentations, Q&A sessions and one-on-one meetings.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is conducting a global Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and is conducting a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. The Company plans to initiate a Phase 3 global pivotal trial under a special protocol assessment (SPA) with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx also plans to initiate Phase 2 clinical trials with aldoxorubicin in patients with late-stage glioblastoma (brain cancer) and Kaposi’s sarcoma. The Company is expanding its pipeline of oncology candidates based on a novel linker platform technology that can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib. CytRx completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), plans to seek a partner for further development of bafetinib, and is evaluating further development of tamibarotene. For more information about CytRx Corporation, visit www.cytrx.com.

Monday, September 23rd, 2013 Uncategorized Comments Off on (CYTR) to Present at the Aegis Capital Corp. 2013 Healthcare Conference

(HZNP) to Present at the 20th Annual NewsMakers in the Biotech Industry Conference

DEERFIELD, IL–(Sep 20, 2013) –  Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Todd Smith, executive vice president and chief commercial officer, will present at the 20th Annual NewsMakers in the Biotech Industry Conference on Friday, September 27th at 3:00 p.m. Eastern Time in New York, NY.  Mr. Smith will provide an overview of the Company and its corporate activities.

The presentation will be webcast live and may be accessed by visiting Horizon’s website at http://ir.horizon-pharma.com. A replay of the webcast will be available for 10 business days.

About Horizon Pharma
Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS/LODOTRA, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company’s strategy is to develop, acquire, in-license and/or co-promote additional innovative medicines where it can execute a targeted commercial approach in specific therapeutic areas while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit www.horizonpharma.com.

Contacts
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
Email Contact

Investors
Kathy Galante
Burns McClellan, Inc.
212-213-0006
Email Contact

Friday, September 20th, 2013 Uncategorized Comments Off on (HZNP) to Present at the 20th Annual NewsMakers in the Biotech Industry Conference

(RGDX) Announces $1.9 Million Registered Direct Offering

Proceeds to be Used for Launch of Recently Acquired FDA-Cleared and Medicare-Reimbursed Test for Difficult to Diagnose Tumors

LOS ANGELES, Sept. 20, 2013  — Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has entered into definitive agreements with institutional investors for the sale of 932,805 shares of its common stock in a registered direct offering at $2.05 per share, the closing price on September 19, 2013. Gross proceeds of the offering, before deducting the placement agent fee and offering expenses, are expected to be approximately $1.9 million.

The offering is expected to close on or about September 25, 2013, subject to the satisfaction of customary closing conditions. Response Genetics intends to use the net proceeds from the offering primarily to expedite the integration of the recently acquired proprietary FDA-cleared and Medicare-reimbursed Tissue of Origin test for difficult to diagnose solid tumors and all associated assets, as more fully described in the Company’s press release dated August 26, 2013 and related Form 8-K.

“This additional capital is primarily intended to facilitate a focused and expedited integration of this portfolio enhancing product,” said Thomas Bologna, Chairman and Chief Executive Officer of Response Genetics. “In conjunction with this effort, we are excited to begin immediate construction of additional laboratory space in our Los Angeles facility. We intend to offer this proprietary Tissue of Origin test, Response Dx: TOOTM, to new and existing customers starting in the first quarter of 2014.”

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), acted as the placement agent for this offering.

The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the registration statement, final base prospectus and accompanying prospectus relating to the offering may be obtained from the Securities and Exchange Commission’s website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., 520 Madison Avenue, 9th Floor, New York, New York 10022.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

About Response Genetics, Inc.

Response Genetics, Inc. (the “Company”) is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company’s technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company’s principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company’s headquarters is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as “project,” “may,” “could,” “would,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan” or similar expressions.

These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

CONTACT: Investor Relations Contact:
         Peter Rahmer
         Trout Group
         646-378-2973

         Company Contact:
         Thomas A. Bologna
         Chairman & Chief Executive Officer
         323-224-3900
Friday, September 20th, 2013 Uncategorized Comments Off on (RGDX) Announces $1.9 Million Registered Direct Offering

(EVI) Announces Year End Results

EnviroStar, Inc. (NYSE MKT:EVI) today reported record revenues and earnings for the year ended June 30, 2013.

Revenues for fiscal 2013 were $36,226,584, an increase of 61.3% over last year’s revenues of $22,457,089. Net earnings increased by 214.1% to $1,607,238, or $.23 per share, compared to $511,689, or $.07 per share in fiscal 2012.

Venerando J. Indelicato, Chief Financial Officer of EnviroStar, Inc., stated: “As previously reported, we received a number of large orders for delivery in fiscal 2013, which we successfully delivered during the year. We are beginning fiscal 2014 with a solid backlog containing a few large orders, and while comparisons will be difficult when comparing fiscal 2014 with our recent banner year, we still expect fiscal 2014 to be a very successful year.”

EnviroStar, Inc. through its subsidiaries is one of the nation’s leading distributors of commercial and industrial laundry and dry cleaning equipment and steam boilers.

This press release contains certain information that is subject to a number of known and unknown risks and uncertainties that may cause actual results and trends to differ materially from those expressed or implied by the forward-looking statements. Information concerning these factors are discussed in Company reports filed with the Securities and Exchange Commission.

EnviroStar, Inc. (NYSE MKT: EVI)
Year ended June 30,
2013 2012
Revenues $ 36,226,584 $ 22,457,089
Earnings before income taxes 2,586,614 828,195
Provision for income taxes 979,376 316,506
Net earnings $ 1,607,238 $ 511,689
Basic and diluted earnings per share $ 0.23 $ 0.07
Weighted average shares outstanding:
Basic and diluted    7,033,732    7,033,732
Friday, September 20th, 2013 Uncategorized Comments Off on (EVI) Announces Year End Results

(FUEL) Prices Initial Public Offering

REDWOOD CITY, Calif., Sept. 20, 2013 — Rocket Fuel Inc. today announced the pricing of its initial public offering of 4,000,000 shares of common stock at a price to the public of $29.00 per share. All of the shares are being offered by Rocket Fuel. The shares are expected to begin trading on the NASDAQ Global Select Market on September 20, 2013 under the symbol “FUEL”. In addition, the underwriters have a 30-day option to purchase up to 600,000 additional shares of common stock at the initial public offering price from certain existing stockholders of Rocket Fuel to cover over-allotments, if any. None of Rocket Fuel’s executive officers are participating in the offering as selling stockholders.

Credit Suisse and Citigroup are acting as joint bookrunners for the offering. Needham & Company, Oppenheimer & Co., Piper Jaffray, BMO Capital Markets, and LUMA Securities are acting as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 19, 2013. The offering will be made only by means of a prospectus. A copy of the prospectus may be obtained by mail from the offices of Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York, 10010, by calling (800) 221-1037, or by emailing a request to newyork.prospectus@credit-suisse.com; or Citigroup Global Markets Inc. c/o Broadridge Financial Solutions, 1155 Long Island Ave., Edgewood, NY 11717, by calling (800) 831-9146, or by emailing batprospectusdept@citi.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

CONTACT: Investor Relations Contact:

         Alex Wellins
         The Blueshirt Group
         415-217-5861
         alex@blueshirtgroup.com

         Media Relations Contact:

         Jessica Cheney
         Atomic
         415-593-1400, ext. 1688
         rocketfuel@atomicpr.com
Friday, September 20th, 2013 Uncategorized Comments Off on (FUEL) Prices Initial Public Offering

(CXM) LifeAgain Announces Recognition Of National Prostate Cancer Awareness Month

LifeAgain Launches BlueMetric Select Term Life Insurance – First Program Designed for Men with Active Localized Prostate Cancer

SAN DIEGO, Sept. 20, 2013 — LifeAgain Insurance Solutions Inc., a wholly-owned subsidiary of Cardium Therapeutics (NYSE MKT: CXM), today announced its recognition of National Prostate Cancer Awareness Month.  September 2013 has been declared National Prostate Awareness Month by Presidential Proclamation to “raise awareness, support research, improve care, and reduce the impact of this disease on our citizens and our Nation.”

Prostate cancer is the most common non-skin cancer in America, affecting 1 in 6 men. In 2013, more than 238,000 men will be diagnosed with prostate cancer, and more than 30,000 men will die from the disease.  It is estimated that over the next 10 years in the United States, approximately 8 million men under age 64 will be determined to have elevated PSA scores (prostate-specific antigen) without formal determination of prostate cancer, and 1 million men under age 64 will be diagnosed with prostate cancer.  Overall, 1.6 million men have elevated PSA, and about 30 percent of them will be diagnosed with prostate cancer.

Currently, men with elevated prostate-specific antigen (PSA) scores and active localized prostate cancer usually are considered uninsurable based on traditional life insurance underwriting standards.  Pioneering this field, LifeAgain recently introduced the first term life insurance for men with active localized prostate cancer. LifeAgain’s BlueMetric Select™ program was specifically designed to assist life insurance companies to provide eligible men with term life insurance coverage following a cancer diagnosis or upon the completion of a prostate cancer surgery, without the traditional multi-year waiting periods and additional medical re-qualifications generally required by most life insurance companies.  Importantly, it is available to prostate cancer patients who are in a “watchful waiting” treatment plan, including younger men who traditionally have been denied life insurance with few exceptions.  The BlueMetric Select program was developed based on LifeAgain’s Advanced Medical Data Analytics Platform Technology (ADAPT™).  Additional information about the BlueMetric Select Program is available at www.lifeagain.com.

About LifeAgain

LifeAgain Insurance Solutions, Inc. is an advanced medical data analytics business and life insurance agency that is focused on the development, marketing and sale of “survivable risk” term life insurance programs for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards.  Working in cooperation with large and established life insurance companies, LifeAgain uses new actuarial methods, and scientific and medical data-driven insights to design life insurance solutions for those who may otherwise not be able to obtain coverage.  LifeAgain’s initial focus is on the development, marketing and sale of survivable risk life insurance for men with active localized prostate cancer.  LifeAgain plans to develop additional new and innovative life insurance solutions for men and women with other medical conditions.  Additional information is available at www.lifeagain.com.

Forward-Looking Statements

This press release includes statements that look forward in time or that express management’s beliefs, expectations or hopes.  Such statements are necessarily based on estimates and assumptions that are inherently subject to significant business, economic, and competitive uncertainties and contingencies, many of which are beyond our control and subject to change. Moreover, we operate in a rapidly changing and competitive environment. These uncertainties and contingencies could cause actual results to differ materially from those expressed, and therefore undue reliance should not be placed upon such statements.  The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this report.

LifeAgain Insurance Solutions Inc. is a life insurance agency incorporated in Delaware and registered in New York as LifeAgain Insurance Services. Insurance issued under the BlueMetric Select program may not be available in all states.

For the education of Producers and Brokers Only – not for public use. 

Copyright 2013 LifeAgain Insurance Solutions Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.lifeagain.com.

LifeAgain®, BlueMetric Select™, Decision Rule Adaption™, and ADAPT™ are trademarks of
LifeAgain Insurance Solutions Inc. or Cardium Therapeutics, Inc.
Other trademarks belong to their respective owners.

Friday, September 20th, 2013 Uncategorized Comments Off on (CXM) LifeAgain Announces Recognition Of National Prostate Cancer Awareness Month

(ISIS) Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study

Improvements in muscle function continue to be observed up to fourteen months after a single dose

CARLSBAD, Calif., Sept. 19, 2013 — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMNRx in children with spinal muscular atrophy (SMA), show that most SMA children receiving the two highest doses of the drug (6 mg and 9 mg) continued to show improvements in muscle function tests up to 14 months after a single injection of the drug.  The Phase 1 data, including these preliminary follow-on data, will be presented at the International Congress of the World Muscle Society by Dr. Kathy Swoboda on Oct. 3, 2013.  SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality.  ISIS-SMNRx is an antisense drug designed to treat all types of SMA.

The preliminary data reported today is from a follow-up analysis of 24 children with SMA who participated in a Phase 1 single-dose, open-label study of ISIS-SMNRx.  Analysis of motor function was performed in these children nine to 14 months following a single dose of ISIS-SMNRx using the Hammersmith Functional Motor Scale-Expanded (HFMSE).  The improvements in HFSME scores were dose dependent with the largest improvements observed in children in the highest dose cohort (9 mg, mean = 5.75). Most children in the 9 mg dose cohort showed continuing improvements during follow up, with no children declining.

“SMA is a devastating disease that results in severe muscle weakness and respiratory compromise in the majority of affected patients. Treating children early in the course of the disease provides the greatest opportunity to reap substantial improvements in muscle strength and function, potentially resulting in a lifetime of benefit. ISIS-SMNRx targets the underlying primary cause of SMA, taking advantage of the backup gene, SMN2, present in all SMA patients,” said Kathryn J. Swoboda, M.D., professor, department of neurology and director of pediatric motor disorders research program at the University of Utah, School of Medicine.  “Preliminary results from Phase 1 clinical trials reveal a favorable safety profile, and appear to indicate that a single dose of the medication at the higher doses tested to date may result in sustained benefit over many months in some children. Thus, while early, we are excited to continue to work closely with Isis in further studies of ISIS-SMNRx in SMA.”

“We are pleased with the progress we are making on ISIS-SMNRx.  Although there was no placebo group, the continuing improvement for up to a year after a single dose observed in this study is encouraging, particularly when considered within the context of the dose response,” said B. Lynne Parshall, chief operating officer at Isis.  “Our ongoing Phase 2 program is proceeding well. The 6 mg dose group in our Phase 2 study in infants with Type I SMA has completed dosing.  Based on the safety, pharmacokinetic and pharmacodynamic profile of ISIS-SMNRx we have observed to date, we have amended the infant study to increase the dose from 9 mg to 12 mg dose. We plan to start dosing this cohort soon.  In our Phase 1b/2a multiple-dose study in children with Type II and Type III SMA, we have completed dosing in all three dose cohorts (3 mg, 6 mg and 9 mg), and we are considering adding a 12 mg dose cohort to this study.  The FDA has expressed reservations about increasing the exposure in children with Type II and Type III SMA, and we are in ongoing discussions with them.  We plan to report data from both of these ongoing studies late this year or early next year.  We also plan to begin our Phase 3 clinical program early next year.”

The Phase 1 study was an open-label, single-dose, dose-escalation study designed to assess the safety, tolerability and pharmacokinetic profile of ISIS-SMNRx in medically stable children from age 2-14.  In this study, children with Type II or Type III SMA received ISIS-SMNRx as a single dose of 1, 3, 6, or 9 mg administered intrathecally.  In addition to measurements of drug concentration in plasma and cerebral spinal fluid, exploratory analyses of changes in motor function were conducted.  Gross motor movements were measured using the HFMSE, a modified version of the Hammersmith Functional Motor Scale.  The HFMSE is used to assess responses on 33 motor function tasks, each scored on a scale from 0 to 2 and allows for assessment of any SMA patient aged 2 or older.  HFMSE has demonstrated good test-retest reliability in other studies.

Data from this study was reported at the American Academy of Neurology in March 2013, showing that a single-dose of ISIS-SMNRx was well tolerated in children with SMA at all dose levels tested and that improvements were observed in HFMSE scores in a number of children, with a mean increase in HFSME scores for the 9 mg cohort at three months was 3.1 points.  The data to be reported at the World Muscle Congress in October is a follow on analysis of HFMSE in 24 children who had completed the Phase 1 study.

ABOUT ISIS-SMNRx
ISIS-SMNRx is designed to alter the splicing of a closely related gene (SMN2) to increase production of fully functional SMN protein.  The United States Food and Drug Administration granted orphan drug status and fast track designation to ISIS-SMNRx for the treatment of patients with SMA.  Isis is currently in collaboration with Biogen Idec to develop and potentially commercialize the investigational compound, ISIS-SMNRx, to treat all types of SMA.  Under the terms of the January 2012 agreement, Isis is responsible for global development and Biogen Idec has the option to license the compound until completion of the first successful Phase 2/3 study.  ISIS-SMNRx is currently being evaluated in two Phase 1b/2a multiple-dose, dose-escalation studies. The first is in children with Type II or Type III SMA. The second is in infants with Type I SMA.

ABOUT SMA
SMA is a severe genetic disease that affects approximately 30,000-35,000 patients in the United States, Europe and Japan. SMA is caused by a loss of, or defect in, the survival motor neuron 1 (SMN1) gene leading to a decrease in the survival motor neuron (SMN) protein. SMN is critical to the health and survival of nerve cells in the spinal cord responsible for neuromuscular growth and function. One in 50 people, the equivalent of about 6 million people in the United States, are carriers of a defective SMN1 gene, which is unable to produce fully functional SMN protein. Carriers experience no symptoms and do not develop the disease. However, when both parents are carriers, there is a one in four chance that their child will have SMA. The severity of SMA correlates with the amount of SMN protein. Infants with Type I SMA, the most severe form of the disease, produce very little SMN protein and have a life expectancy of less than two years. Children with Type II have greater amounts of SMN protein but still have a shortened lifespan and are never able to stand independently. Children with Type III have a normal lifespan but accumulate life-long physical disabilities as they grow.

Isis acknowledges support from the following organizations for ISIS-SMNRx: Muscular Dystrophy Association, SMA Foundation, Families of SMA and intellectual property licensed from Cold Spring Harbor Laboratory and the University of Massachusetts Medical School.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis’ broad pipeline consists of 30 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis’ partner, Genzyme, is commercializing Isis’ lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Isis’ patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS’ FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis’ strategic alliance with Biogen Idec, the planned clinical studies for ISIS-SMNRx and the discovery, development, activity, therapeutic and commercial potential and safety of ISIS-SMNRx to treat patients with SMA.  Any statement describing Isis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis’ programs are described in additional detail in Isis’ annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, “Isis,” “Company,” “we,” “our,” and “us” refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.

Thursday, September 19th, 2013 Uncategorized Comments Off on (ISIS) Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study

(KNDI) Announces Chinese Govt Issued 2013-2015 EV Subsidy Policy

Jinhua, China–(September 19, 2013) – Kandi Technologies Group, Inc. (NASDAQ: KNDI) (the ‘Company’ or ‘Kandi’), today announced that the Chinese government finally unveiled its long anticipated subsidy policy for new energy vehicles upon the approval by the State Council. On September 17, 2013, the Ministry of Finance, the Ministry of Science and Technology, the Ministry of Industry and Information Technology and the National Development and Reform Commission (the “Four Ministries”) jointly issued Notice No. 551 of 2013, titling “Regarding the Continuous Promotion and Application of New-Energy Vehicles for the years from 2013 to 2015” (the “Notice”).

The subsidiary policy, which covers the pure electric vehicles, plug-in hybrid electric vehicles and fuel cell battery vehicles, aims to increase the efforts on promotion of new energy vehicle procurement with government agencies, public organizations and public transportation areas. According to the Notice, the central government will provide, based on certain technical requirement, up to RMB 60,000 (approximately USD 9,800) for the purchase of an all-electric passenger vehicle and up to RMB 500,000 (approximately USD 81,700) for the purchase of an electric bus. The subsidy payments will be distributed to the manufacturers on a quarterly basis in advance and the subsidies will then be paid by the manufacturers directly to the consumers.

The Notice also established the following benchmark requirements for the pilot cities or regions:

1. From 2013 to 2015, there shall be no less than 10,000 new energy vehicles added cumulatively in each Large Pilot City or Region, and no less than 5,000 new energy vehicles added cumulatively in each of other cities or regions;

2. No less than 30% of these new energy vehicles shall be non-local brands. The local government shall not set barriers or disguised restrictions for vehicles from other regions.

3. The vehicle procurements by the government agencies and public organizations shall favor new energy vehicles. For new or replacement public transportation vehicles, government agency vehicles, logistic vehicles and waste management vehicles, no less than 30% of them shall be new energy vehicles.

4. The local government shall have issued specific policies and measures of vehicle purchase, public transportation operation, supporting infrastructure construction, and other aspects for new energy vehicles;

5. The pilot cities are subject to an annual inspection and evaluation. Pilot cities, which fail to complete the annual promotion objectives, will be eliminated from the subsidy program.

Any city that meets the requirements above can apply to become a pilot city and qualify to receive the subsidies. This policy will expand the geographic areas for the promotion of new energy vehicle in China. Before October 15, 2013, all interested city shall prepare a detailed new energy vehicle promotion implementation plan and submit it to the Four Ministries for their evaluation and final approval to be on the pilot city list.

For more information about the Notice, please refer to the official Chinese government release http://jjs.mof.gov.cn/zhengwuxinxi/tongzhigonggao/201309/t20130916_989833.html.

Mr. Xiaoming Hu, Chairman and Chief Executive Officer of Kandi, commented, “We are really excited about this long awaited government subsidy policy. The subsidy for the new energy vehicles will be directly distributed to the manufacturers from the central government, which will improve the transparency in the market competition. Furthermore, the pure electric vehicle is still the main focus in the policy, which will be very beneficial to a variety of Kandi’s pure EV projects. We believe the cities that are currently implementing mini-public transportation EV sharing systems will be qualified as pilot cities for the subsidies. Kandi will update the market accordingly when these cities receive the approvals of their applications.”

About Kandi Technologies Group, Inc.

Kandi Technologies Group, Inc. (NASDAQ: KNDI), headquartered in Jinhua, Zhejiang Province, is engaged in the research and development, manufacturing and sales of various vehicles. Kandi has established itself as the one of the world’s largest manufacturer of pure electric vehicles (EVs), Go-Kart vehicles, and tricycle and utility vehicles (UTVs), among others. More information can be viewed at its corporate website is http://www.kandivehicle.com.

Safe Harbor Statement

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on the SEC’s website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contact:

Kandi Technologies Group, Inc.

China:
Email: IR@kandigroup.com
Phone: 86-579-82239856

U.S.A.:
Email: IR@kandigroup.com
Phone: 1-212-551-3610

Thursday, September 19th, 2013 Uncategorized Comments Off on (KNDI) Announces Chinese Govt Issued 2013-2015 EV Subsidy Policy

(PGRX) $20M Strategic Investment Letter of Intent to Prospect Global Resources

Sichuan Chemical Industry Holding (Group) Co., Ltd. (“Sichuan”) has issued Prospect Global Resources Inc. (“Company” or “Prospect”) a Letter of Intent indicating interest in up to a $20 million strategic investment in Prospect to further the development of the Company’s Holbrook Project. Prospect and Sichuan Chemical entered into a potash supply agreement in 2012.

Xiaojun Chen, Chairman of Sichuan Chemical’s Board of Directors, stated, “Sichuan has been looking for ways to deepen its cooperation with PGRX. We look forward to working with PGRX in order to bring its Holbrook Basic project to completion and Sichuan will continue to pursue additional avenues of cooperation going forward.”

The Company recently released the results of a Pre-Feasibility Study and is underway on its infill-drilling program. Prospect plans to complete a Definitive Feasibility Study by the third quarter of 2014.

Terms of the Sichuan investment are to be agreed to and subject to final approval by the Sichuan Provincial Government and affiliates.

About Prospect Global Resources Inc.

Prospect Global Resources Inc. is a Denver-based company engaged in the exploration and development of a potash mine located in the Holbrook Basin of eastern Arizona. Prospect Global’s stock is traded on the NASDAQ Capital Market under the ticker symbol PGRX.

Additional details about Prospect Global Resources Inc. can be viewed at the Company’s website, www.prospectgri.com.

Source: Prospect Global Resources Inc.

About Sichuan Chemical Industry Holding (Group) Co., Ltd.

Sichuan Chemical Industry Holding (Group) Co., Ltd. (SCIHC) is a provincial state-owned enterprise with assets of RMB 20 billion. It is a large-scale conglomerate involved in production and marketing of fertilizers and chemical products, including phosphorite and coal. Additional business lines include international commodities trade and chemical and technical services. SCIHC has 24,300 full-time employees, more than 5,000 of whom are technical professionals. Sichuan Chemical has been a leader of China’s chemical industry for more than 50 years.

Source: Sichuan Chemical Industry Holding (Group) Co., Ltd.

Regarding Forward-Looking Statements

With the exception of historical matters, the matters discussed in this press release include forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from projections or estimates contained herein. Such forward-looking statements include statements regarding current and future classification of Prospect Global’s potash resources, development of its potash resources and potash mining facility and the Pre-Feasibility Study. Factors that could cause actual results to differ materially from projections or estimates include, among others, potash prices, economic and market conditions, and the additional risks described in Prospect Global’s filings with the SEC, including Prospect Global’s Annual Report on Form 10-K for the year ended March 31, 2013. Most of these factors are beyond Prospect Global’s ability to predict or control. The forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, Prospect Global does not assume any obligation to update any forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements.

Thursday, September 19th, 2013 Uncategorized Comments Off on (PGRX) $20M Strategic Investment Letter of Intent to Prospect Global Resources

(CXM) LifeAgain Supports Life Insurance Awareness Month

LifeAgain Launches BlueMetric Select Term Life Insurance – First Program Designed for Men with Active Localized Prostate Cancer

SAN DIEGO, Sept. 19, 2013 — LifeAgain Insurance Solutions Inc., a wholly-owned subsidiary of Cardium Therapeutics (NYSE MKT: CXM), today announced its support of Life Insurance Awareness Month.  The campaign, taking place during September, is sponsored by the Life and Health Insurance Foundation for Education (LIFE).  LIFE is dedicated to helping individuals take personal financial responsibility through the ownership of life insurance and other related insurance, including disability and long-term care insurance, to ensure their loved ones are financially protected.

While life insurance rates for the traditional insurable population are now more affordable than ever, the percentage of U.S. households owning individual life insurance has steadily declined over the past 25 years—from 62 percent in 1985 to an all-time 50-year low of 44 percent in 2010.  However, for cancer patients who really do “need life insurance,” their hands often are tied. Life insurance typically only becomes an option after five years of being cancer free.  Even then, it can be an uphill battle depending on the type, stage, grade of the cancer, and the treatment plan.

To address this problem, LifeAgain recently launched its BlueMetric™ Select term life insurance program for men with active localized prostate cancer.  The BlueMetric Select program was developed based on LifeAgain’s Advanced Medical Data Analytics Platform Technology (ADAPT™).  Prostate cancer is one of the most prevalent forms of cancer in the United States. Currently, men with elevated prostate-specific antigen (PSA) scores and active localized prostate cancer usually are considered uninsurable based on traditional underwriting standards.  LifeAgain’s BlueMetric Select program was specifically designed to assist life insurance companies to provide eligible men with term life insurance coverage following a cancer diagnosis or upon the completion of a prostate cancer surgery, without the traditional multi-year waiting periods and additional medical re-qualifications generally required by most life insurance companies.  Additional information about the BlueMetric Select Program is available at www.lifeagain.com.

About The Life and Health Insurance Foundation for Education

The Life and Health Insurance Foundation for Education (LIFE) is a nonprofit organization dedicated to helping consumers make smart insurance decisions to safeguard their families’ financial futures. LIFE’s mission is to educate the public about the essential role of life and health insurance in sound financial and retirement planning and the value added by insurance agents and other financial advisors. Visit www.lifehappens.org.

About LifeAgain

LifeAgain Insurance Solutions, Inc. is an advanced medical data analytics business and life insurance agency that is focused on the development, marketing and sale of “survivable risk” term life insurance programs for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards.  Working in cooperation with large and established life insurance companies, LifeAgain uses new actuarial methods, and scientific and medical data-driven insights to design life insurance solutions for those who may otherwise not be able to obtain coverage.  LifeAgain’s initial focus is on the development, marketing and sale of survivable risk life insurance for men with active localized prostate cancer.  LifeAgain plans to develop additional new and innovative life insurance solutions for men and women with other medical conditions.  Additional information is available at www.lifeagain.com.

Forward-Looking Statements

This press release includes statements that look forward in time or that express management’s beliefs, expectations or hopes.  Such statements are necessarily based on estimates and assumptions that are inherently subject to significant business, economic, and competitive uncertainties and contingencies, many of which are beyond our control and subject to change. Moreover, we operate in a rapidly changing and competitive environment. These uncertainties and contingencies could cause actual results to differ materially from those expressed, and therefore undue reliance should not be placed upon such statements.  The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this report.

LifeAgain Insurance Solutions Inc. is a life insurance agency incorporated in Delaware and registered in New York as LifeAgain Insurance Services. Insurance issued under the BlueMetric™ Select program may not be available in all states.  For the education of Producers and Brokers Only – not for public use.

Copyright 2013 LifeAgain Insurance Solutions Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.lifeagain.com.

LifeAgain®, BlueMetric™, Decision Rule Adaption™, and ADAPT™ are trademarks of
LifeAgain Insurance Solutions Inc. or Cardium Therapeutics, Inc.
Other trademarks belong to their respective owners.

Thursday, September 19th, 2013 Uncategorized Comments Off on (CXM) LifeAgain Supports Life Insurance Awareness Month

(CLPI) CEO H. Montgomery Discusses Indian Subsidiary, Money-on-Mobile w/ CorporateProfile.com

While in New York City presenting at the 15th annual Rodman & Renshaw Conference, Calpian (OTC: CLPI) CEO Harold Montgomery discusses the services platform of its Indian subsidiary, Money-on-Mobile, the Indian leader in pre-paid mobile payment solutions. With over 157,800 retail locations nationwide, MoM is the consumer’s choice for mobile payments.

Or, you can view by clicking here: http://www.corporateprofile.com/2013/09/18/interview-w-calpian-inc-clpi-ceo-harold-montgomery/

Calpian, Inc.

Calpian, Inc. (CLPI) is a publicly traded company with corporate offices in Dallas, Texas, operating centers in Georgia, and New York and mobile payments emerging-market operations through its subsidiary in India.

Calpian’s Indian subsidiary offers Money-on-Mobile, a pre-paid mobile payment solution, to more than 157,000 Indian retail locations. Calpian’s management team has over 70 years in combined experience in the payments business. Calpian’s CEO, Harold Montgomery, is a recognized industry leader who has provided expert testimony to the U.S. Congress and Federal Reserve Bank on payments-related issues and regularly appears in numerous industry publications, such as Transaction World Magazine. Please visit our website at www.calpian.com for more information.

About Corporate Profile®

Corporate Profile® is a multi-media news provider, creating original daily news segments and interviews covering topics including finance, fashion, medicine, charitable causes, lifestyle, and wellness through www.corporateprofile.com. Financial segments are broadcast on www.cpreports.com, which provides viewers and readers fresh, original, and highly informative ideas and market commentary from Wall Street.

Thursday, September 19th, 2013 Uncategorized Comments Off on (CLPI) CEO H. Montgomery Discusses Indian Subsidiary, Money-on-Mobile w/ CorporateProfile.com

(RWC) RELM Wireless Receives U.S. Military Order Totaling $1.2 Million

– For UHF & 800MHz P25 Trunked Portable Radios and Repeaters –

WEST MELBOURNE, Fla., Sept. 18, 2013 — RELM Wireless Corporation (NYSE MKT: RWC) today announced that it received an order totaling approximately $1.2 million from a branch of the U.S. Military for the Company’s KNG P25 trunked portable UHF and 800MHz radios and rapid-deployment repeaters.  It is anticipated that the order will be fulfilled during the third quarter of 2013.

RELM President and Chief Executive Officer David Storey commented, “We are very pleased to announce a substantial order from a new U.S. military customer.  This order is encouraging in several respects.  Not only is the order from a first-time customer, it is for KNG products in the UHF and 800MHz bands, including trunking.  It was just a short time ago that we were unable to compete for requirements such as these.  The development and introduction of the KNG product line over the past few years has expanded our addressable market and enables us to win such opportunities.  We are focused on replicating this kind of order with more new military and public safety customers.”

About APCO Project 25 (P25)

APCO Project 25 (P25), which requires interoperability among compliant equipment regardless of the manufacturer, was established by the Association of Public-Safety Communications Officials and is approved by the U.S. Department of Homeland Security.  The shift toward interoperability gained momentum as a result of significant communications failures in critical emergency situations.  RELM was one of the first manufacturers to develop P25-compliant technology.

About RELM Wireless Corporation

As an American Manufacturer for more than 65 years, RELM Wireless Corporation has produced high‑specification two‑way communications equipment of unsurpassed reliability and value for use by public safety professionals and government agencies, as well as radios for use in a wide range of commercial and industrial applications.  Advances include a broad new line of leading digital two‑way radios compliant with APCO Project 25 specifications.  RELM’s products are manufactured and distributed worldwide under BK Radio and RELM brand names. The Company maintains its headquarters in West Melbourne, Florida and can be contacted through its web site at www.relm.com or directly at 1‑800‑821‑2900.  The Company’s common stock trades on the NYSE MKT market under the symbol “RWC”.

This press release contains certain forward-looking statements that are made pursuant to the “Safe Harbor” provisions of the Private Securities Litigation Reform Act Of 1995.  These forward-looking statements concern the Company’s operations, economic performance and financial condition and are based largely on the Company’s beliefs and expectations.  These statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Such factors and risks include, among others, the following: changes or advances in technology; the success of our LMR product line; competition in the land mobile radio industry; general economic and business conditions, including federal, state and local government budget deficits and spending limitations; the availability, terms and deployment of capital; reliance on contract manufacturers and suppliers; heavy reliance on sales to agencies of the U.S. government; our ability to utilize deferred tax assets; retention of executive officers and key personnel; our ability to manage our growth; government regulation; business with manufacturers located in other countries; our inventory and debt levels; protection of our intellectual property rights; fluctuation in our operating results; acts of war or terrorism; any infringement claims; provisions in our charter documents and under Nevada law that may discourage a potential takeover; maintenance of our NYSE MKT listing; and the effect on our stock price and ability to raise equity capital of future sales of shares of our common stock. Certain of these factors and risks, as well as other risks and uncertainties, are stated in more detail in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012 and in the Company’s subsequent filings with the SEC.  These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements.

Wednesday, September 18th, 2013 Uncategorized Comments Off on (RWC) RELM Wireless Receives U.S. Military Order Totaling $1.2 Million

(ATEA) Alliance 11.0 Continues Tradition of Delivering Innovation

Powerful and Advanced Capabilities will Empower Organizations to Revolutionize the Way they Provide Service

HORSHAM, Pa., Sept. 18, 2013 — Astea International Inc. (NASDAQ:ATEA), a global provider of service lifecycle management and mobility solutions, has introduced a new release of the industry’s most robust solution to meet the evolving needs of global service organizations. The significant investment in development has resulted in an unprecedented release that creates a paradigm shift away from the traditional service management solutions in the market today. With this release, Astea has introduced an abundance of new features and enhancements that were developed on the premise of three main underlying concepts; optimizing and streamlining processes, enabling proactive service insight and intelligence at every level, and significantly increasing ease of use and customizations without technical skills. Accelerated revenue growth, proactive intelligence, productivity and process optimization, enriched employee interaction experience, and increased customer satisfaction are just a few of the advantages organizations will be able to achieve with this new release.

The majority of service organizations already recognize that service management and mobile workforce solutions are mission-critical components to their overall strategy in order to fuel growth, derive competitive differentiation, and ultimately achieve the highest levels of customer satisfaction. Now, forward-thinking organizations are looking at how they can deliver more predictive and proactive service to adapt to the ever changing and increasing demands of their customers. With Astea Alliance 11.0, companies can do just that, deploy in the cloud or on premise, from a single solution provider. For more than 34 years, Astea has been developing and implementing global solutions solely focused on providing service organizations with technology innovations that will further optimize and accelerate their business, and this release continues that tradition.

Below are just a fraction of the features and enhancements in Astea Alliance 11.0 that accelerates innovation to transform the way companies provide exemplary service:

  • Productivity and Process Optimization –When it comes to workforce management, having too many or too few resources can dramatically impact a service organization’s ability to provide superior service. With Astea’s new Workforce Planning module, organizations will be able to ensure that they have the right amount of resources, with the right skill sets, at the right time, in the right geography to meet demand while optimizing resources and costs. Service organizations will be able to create, monitor and proactively adjust plans, in real-time, to ensure optimal resource utilization across the organization. When it comes to empowering the technician in the field and improving productivity, Astea has consistently delivered. Now, Astea has shifted the focus on enabling the technician to become a source of new revenue generation by enabling the technician to identify, quote, and sell products and services while on site at the customer. Additionally, Astea has developed extensive process optimization facilities pervasive throughout their entire solution suite. By adding more workflow wizards, increasing “one click” updates, and further compressing processes, service organizations will be able to increase efficiencies and provide faster service to their customers.
  • Proactive Service Insight and Intelligence at Every Level – Astea has developed Smart Checklist functionality that will enable organizations with the ability to create unlimited, conditional branching checklists and learning guides that can assist the back office or technician in the field to accurately diagnose, troubleshoot, record key information, follow instructions based on specific responses, and ultimately resolve the issue the first time. When it comes to enabling intelligence, Astea has a long history of providing embedded dashboards and contextual reports throughout the application. With this latest release, Astea is extending its powerful reporting and business intelligence framework. Delivering easy-to-use report creation and end-user personalization capabilities, without needing any technical or programming skills, will provide even more meaningful and relevant metrics and key performance indicators at every level. Astea has also introduced innovative Operational Heatmaps that combine geographic data with business and demographic data for highly interactive dashboard visualizations that enrich understanding and lead towards rapid identification of key insights for better decision making across the service enterprise.
  • Ease of Use, Customizations without Code, and Connecting with the Enterprise – By leveraging Astea’s intuitive, point and click interface, non-programmers can easily customize without code to quickly adapt the solution to the dynamic needs of their business. Additionally, Astea’s HTML5 mobile platform users can leverage the groundbreaking Mobile Options Editor tool to modify the mobile application without needing technical skills or learning a separate development application. When it comes to sharing information with existing ERP, CRM or other solutions, Astea provides an extensible platform that is designed to easily integrate with existing systems within a company’s infrastructure. Astea has added numerous plug-and-play connectors to ensure that relevant information is shared and exchanged across the enterprise. The newest connectors that have been added to their existing portfolio of integrations are: Salesforce.com, Oracle JDEdwards, Microsoft Dynamics (CRM, AX, NAV, GP), and Quickbooks.

“Building on our extensive history and expertise in the service management industry, Astea Alliance 11.0 has achieved a new standard of delivering a powerful, feature-rich, forward-thinking solution that offers greater ease of use, unmatched configurability, accelerates and optimizes productivity, and provides unique ways to deliver knowledge throughout the organization to ensure user adoption that ultimately ends with elated customers,” said Zack Bergreen, CEO of Astea International. “We intimately understand that companies are under constant pressure to do more work with fewer resources. Simultaneously, service organizations are being tasked with increasing service revenues and creating competitive differentiation to offset product commoditization. This new release has a heightened focus on delivering functionality and flexibility that will enable organizations to accomplish those challenges without complexity.”

Astea is the only solution provider that offers all cornerstones of service lifecycle management: customer management; service management; asset management; forward and reverse logistics management; and mobile workforce management with enhanced scheduling optimization. Astea’s solutions are seamlessly orchestrated to share and leverage information throughout the service lifecycle – removing the traditional barriers between the field and back office. With Astea Alliance’s modularity, companies can introduce one module at a time or deploy a seamless information backbone across the entire service lifecycle continuum, thereby eliminating the patchwork of disparate systems that can hamper a company’s ability to provide best-in-class.

About Astea International
Astea International (NASDAQ: ATEA) is a global provider of software solutions that offer all the cornerstones of service lifecycle management, including customer management, service management, asset management, forward and reverse logistics management and mobile workforce management and optimization. Astea’s solutions link processes, people, parts, and data to empower companies and provide the agility they need to achieve sustainable value in less time, and successfully compete in a global economy. Since 1979, Astea has been helping more than 600 companies drive even higher levels of customer satisfaction with faster response times and proactive communication, creating a seamless, consistent and highly personalized experience at every customer relationship touch point.

www.astea.com.   Service Smart.  Enterprise Proven.

© 2013 Astea International Inc. Astea and Astea Alliance are trademarks of Astea International Inc. All other company and product names contained herein are trademarks of the respective holders.

Wednesday, September 18th, 2013 Uncategorized Comments Off on (ATEA) Alliance 11.0 Continues Tradition of Delivering Innovation

(ATOS) Genetics Signs Distribution Agreement With McKesson Medical-Surgical

SEATTLE, WA–(Sep 18, 2013) – Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that it has entered into a nationwide distribution agreement with McKesson Medical-Surgical to sell and distribute Atossa’s MASCT device and patient collection kits. The MASCT device is used in OB/GYN, primary care, and women’s clinics to perform a non-invasive collection of breast fluid. The specimens are analyzed at the National Reference Laboratory for Breast Health, a subsidiary of Atossa, with the ForeCYTE Breast Health Test, which assesses a woman’s future risk of breast cancer.

Under terms of the agreement, McKesson Medical-Surgical will sell and distribute the MASCT device and patient collection kits nationwide through its sales force.

Dr. Steven C. Quay, Chairman, President & CEO of Atossa Genetics, commented, “Our agreement with McKesson Medical-Surgical is another important step forward in making the ForeCYTE test the standard of care in breast cancer risk assessment. McKesson Medical-Surgical is one of the country’s top medical distributors and we are pleased that they have agreed to add the ForeCYTE test to their product portfolio. With their extensive market presence, we look forward to providing physicians a much needed early warning system by detecting the earliest, reversible precursors of breast cancer.”

“We’re pleased to be able to offer Atossa Genetics’ products to our customers,” said Joan Eliasek, Senior Vice President, Supplier Management, McKesson Medical-Surgical. “As a company, we are in business for one reason: better health. And fighting cancer is a major aspect of better health in our country. That’s why Mckesson’s corporate citizenship initiative is focused on supporting the fight against cancer. We are glad to offer products to our customers that help them deliver better care for their patients.”

Chris Destro, Vice President, Sales and Marketing for Atossa, stated, “McKesson Medical-Surgical will enable us to further increase our penetration into all geographical markets while expanding our relationships with physician offices. With a large sales force calling on physician practices, we look forward to working closely with the McKesson Medical-Surgical sales team.”

Breast cancer is the second most common form of cancer. One woman is diagnosed every minute. Current detection methods lack the ability to detect very small concentrations of precancerous cells (ductal hyperplasia) at breast cancer’s earliest stages. Early detection enables lifestyle change and/or chemopreventative treatment to reverse the abnormal cells. Atossa’s ForeCYTE Breast Health Test has been shown in analytical validation to detect as few as 10 precancerous breast cells.

About the ForeCYTE Breast Health Test

The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician’s office. A small sample of fluid, aspirated from the nipple of each breast with the Company’s MASCT device, can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test and the test is painless.

Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the pre-cancer changes that can lead to breast cancer and the treatment of those early changes.

About McKesson Medical-Surgical

McKesson Medical-Surgical Inc., with offices in Richmond, VA, and McKesson Medical-Surgical Minnesota Supply Inc. in Golden Valley, MN, are affiliates of the McKesson Corporation. McKesson, currently ranked 14th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. We work with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit www.mckesson.com.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and by providing, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information on Atossa, please visit www.atossagenetics.com. For additional information on the ForeCYTE test and the NRLBH, please visit www.nrlbh.com.

Atossa Genetics Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa’s ability to continue to manufacture and sell its products, the efficacy of Atossa’s products and services, the market demand for and acceptance of Atossa’s products and services, performance of distributors and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Contact:

Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel
(O) 800-351-3902
Email Contact

MBS Value Partners
Matthew D. Haines (Investors)
Managing Director
(O) 212-710-9686
Email Contact

JQA Partners
Jules Abraham (Media)
Principal
(O) 917-885-7378
Email Contact

Wednesday, September 18th, 2013 Uncategorized Comments Off on (ATOS) Genetics Signs Distribution Agreement With McKesson Medical-Surgical

(AXU) Extends Flame & Moth to More Than 900 Meters in Strike Length

Alexco Extends Flame & Moth to More Than 900 Meters in Strike Length; Silver Grades to 28.8 Ounces per Ton over 5.6 Meters

VANCOUVER, BRITISH COLUMBIA–(Sept. 18, 2013) – Alexco Resource Corp. (NYSE MKT:AXU)(TSX:AXR) today announced the results of the 2013 surface drilling program targeting extension of the Flame & Moth deposit, centrally located within the Keno Hill Silver District in Canada’s Yukon Territory. Drilling has confirmed a further 220-meter extension of the mineralized Flame vein to the southwest of the previously defined silver resource of 22.9 million ounces Indicated and 1.1 million ounces Inferred (see news release dated January 31, 2013 “Alexco Expands Flame & Moth Indicated Resource to 22.9 Million Ounces of Silver; Resource Grade Increased, Deposit Remains Open”). The deposit remains open down plunge to the southwest, and to the northeast. In addition, results from 2013 surface drilling at the Bulldozer prospect approximately one-half kilometer west of the Flame & Moth deposit have returned up to 28.7 ounces per ton (opt) silver over 0.85 meters on a separate but probably related structure.

Alexco President and Chief Executive Officer Clynt Nauman said, “There is no doubt that the Flame & Moth deposit is one of the best discoveries in the Keno Hill Silver District in the last 50 years. It is a potential game changer for Alexco and will materially influence the way this District is developed in the future. The 2013 drilling indicates another opportunity to further significantly increase the resource base in this robust deposit. Although Flame & Moth was originally a blind discovery from the surface, the silver, lead, zinc and gold deposit and associated mineralized structure can now be traced for almost a kilometer along strike. The mineralization exhibits true widths ranging from approximately 0.5 meters to more than 11 meters, averaging approximately four meters, with grades between 400 grams per tonne (gpt) to more than 1,400 gpt silver depending on cutoff, remains open, and is located adjacent to our existing infrastructure and mill. Furthermore, the newly defined Bulldozer discovery approximately one-half kilometer to the west of Flame & Moth indicates the presence of a locally mineralized NNE-SSW trending corridor that is prospective over two kilometers in the immediate Christal Lake area and is interpreted to extend a further six kilometers northeast to the Sadie Ladue deposit.”

Highlights

Final 2013 exploration drill results for the Flame and Bulldozer prospects include the following significant composite or individual assay intervals (above 30 gpt silver):

Flame Southwest Lightning Zone

  • K-13-0504 intersected mineralized vein material over 5.56 meters true width from 327.64 meters with a composite assay of 987 gpt (28.8 opt) silver, 0.38 gpt gold; including 0.62 meters true width from 330.67 meters with an assay of 2,414 gpt (70.4 opt) silver, 0.55 gpt gold.
  • K-13-0506 intersected mineralized vein material over 4.33 meters true width from 418.85 meters with a composite assay of 436 gpt (12.7 opt) silver; including 0.66 meters true width from 418.85 meters with an assay of 1,980 gpt (57.8 opt) silver.
  • K-13-0505 intersected mineralized vein material over 6.42 meters true width from 340.37 meters with a composite assay of 150 gpt (4.4 opt) silver, 0.2 gpt gold; including 0.85 meters true width from 344.15 meters with an assay of 752 gpt (21.9 opt) silver, 0.46 gpt gold.

Bulldozer Vein

  • K-13-0494 intersected mineralized vein material over 0.85 meters true width from 186.88 meters with a composite assay of 985 gpt (28.7 opt) silver, 0.36 gpt gold; including 0.25 meters true width from 187.07 meters with an assay of 2,640 gpt (77 opt) silver 0.33 gpt gold.

2013 Flame & Moth Geology and Updates

The 2013 surface exploration program comprised 13 drill holes for a total of 2,829 meters in the area centered on the Flame & Moth deposit.

Three diamond drill holes for a total of 1,257 meters completed on the southwest extension of the Lightning zone demonstrate that the mineralized zone extends at least 220 meters further along strike and more than 290 meters down plunge from the nearest existing drill hole. This results in a total strike length in excess of 900 meters to the known extent of the mineralization in the Flame vein. The deposit remains open further down plunge to the southwest while the mineral controlling structure is known to extend and be open to the northeast and at depth.

In the 2013 Lightning zone extension drill holes, the vein maintains consistent true thicknesses of between 4.33 and 6.42 meters with silver grades to 28.8 opt over 5.56 meters true thickness, and demonstrates the potential to significantly increase the resource base of this robust deposit.

Additional drilling of four holes for 493 meters was also completed in the very shallow upper part of the Christal zone. These holes indicate a local weakening of the mineralization in the upper 60 meters although the structure is still present coming to the subsurface very close to the existing District mill. Interestingly, it may be this local weakening of mineralization in an area of locally shallow overburden that resulted in this deposit remaining undiscovered over the decades. One further drill hole was completed for 86 meters and confirmed the southwest extension of the Moth vein in the hangingwall section of the Mill Fault.

At the nearby Bulldozer prospect a further five holes were completed for 1,042 meters. These intercepted a significant structure that is in places well mineralized and demonstrates that the vein discovered in 2012 has an orientation similar to the Flame vein, confirming it to represent a separate structure. A mineralized intercept of 0.85 meters true width with a composite assay of 28.7 opt was obtained, making this structure a high priority future exploration target.

Taken together, results from the 2013 Flame drilling when combined with the Bulldozer discovery indicate the possible presence of a broad, locally mineralized structural corridor at least one-half kilometer wide extending at least two kilometers along a NNE-SSW trend, possibly centered on the Flame & Moth discovery. This corridor requires significantly more drilling, and remains the top priority exploration target in the district.

Updated composite assay tables, along with a drill hole location map and a long section plot, for 2013 drill holes completed at the Flame & Moth prospect are appended to this release, and are also available for review on the Company’s website at www.alexcoresource.com.

The 2013 exploration drill program and sampling protocol has been reviewed, verified and compiled by Alexco’s geologic staff under the supervision of Alan McOnie, Vice President, Exploration for Alexco and a Qualified Person as defined by National Instrument 43-101. A rigorous quality control and quality assurance protocol is used on the project, including blank, duplicate and standard reference samples in each batch of 20 samples delivered to the assay lab. Drill core samples were shipped to ALS Minerals Labs at Whitehorse, Yukon Territory for preparation, with fire assay and multi-element ICP analyses completed at the ALS Minerals facility in North Vancouver, British Columbia. The disclosure of scientific and technical information about Alexco’s mineral projects contained in this news release has also been reviewed and approved by Mr. McOnie.

About Alexco

Alexco Resource Corp. owns the Bellekeno silver mine, one of several mineral properties held by Alexco which encompass substantially all of the historical Keno Hill Silver District located in Canada’s Yukon Territory. Bellekeno, which commenced commercial production at the beginning of calendar year 2011, was Canada’s only operating primary silver mine from 2011 to 2013. Alexco recently announced a suspension of operations at Bellekeno in order to decrease costs and reposition the District for long-term, sustainable operations. The Keno Hill Silver District lies within the traditional territory of the First Nation of Na-Cho Nyak Dun who have a fully settled land claim agreement with the Government of Canada and the Yukon, and Alexco operates within the District under a comprehensive cooperation and benefits agreement with the First Nation. Alexco’s primary near-term exploration objective is to unlock value in the silver-rich Keno Hill District, and is focused on growth by advancing its promising District properties to development decisions. Employing a unique business model, Alexco also provides mine-related environmental services, remediation technologies and reclamation and mine closure services to both government and industry clients through the Alexco Environmental Group, its wholly-owned environmental services division.

Keno Hill Silver District History

Between 1921 and 1988, the Keno Hill Silver District was a world-class silver producer, with more than 217 million ounces of silver produced at average grades of 40.5 ounces per ton silver, 5.6% lead and 3.1% zinc (Yukon Government’s Minfile database). These historical production grades would rank Keno Hill in the top 3% by grade of today’s global silver producers.

Some statements (“forward-looking statements”) in this news release contain forward-looking information concerning the Company’s anticipated results and developments in the Company’s operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future, made as of the date of this news release. Forward-looking statements may include, but are not limited to, statements with respect to future remediation and reclamation activities, future mineral exploration, the estimation of mineral reserves and mineral resources, the realization of mineral reserve and mineral resource estimates, future mine construction and development activities, future mine operation and production, the timing of activities and reports, the amount of estimated revenues and expenses, the success of exploration activities, permitting time lines, requirements for additional capital and sources and uses of funds. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Such factors include, among others, risks related to actual results of exploration and development activities; actual results of mining activities; actual results of consulting activities; actual results of remediation and reclamation activities; conclusions of economic evaluations; changes in project parameters as plans continue to be refined; future prices of silver, gold, lead, zinc and other commodities; possible variations in mineable resources, grade or recovery rates; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the mining industry; First Nation rights and title; continued capitalization and commercial viability; global economic conditions; competition; and delays in obtaining governmental approvals or financing or in the completion of development activities. Forward-looking statements are based on certain assumptions that management believes are reasonable at the time they are made. In making the forward-looking statements included in this news release, the Company has applied several material assumptions, including, but not limited to, the assumption that market fundamentals will result in sustained silver, gold, lead and zinc demand and prices. There can be no assurance that forward-looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.

To view the Appendices, click the following link: http://media3.marketwire.com/docs/AXR%20Appendix.pdf.

Alexco Resource Corp.
Clynton R. Nauman
President and Chief Executive Officer
(604) 633-4888
info@alexcoresource.com
www.alexcoresource.com

Wednesday, September 18th, 2013 Uncategorized Comments Off on (AXU) Extends Flame & Moth to More Than 900 Meters in Strike Length

(FNRG) MissionIR Features ForceField Energy CEO David Natan in Exclusive Interview

ATLANTA, GA–(Sep 18, 2013) –  MissionIR today announces that its interview with David Natan, the Chief Executive Officer of ForceField Energy Inc. (OTCQB: FNRG), is now available online. The audio interview can be heard at http://fnrg.missionir.com/interview.html.

In the interview, Natan provides an overview of the rapidly growing energy sectors being targeted by the Company’s multifaceted business model. He discusses ForceField Energy’s proprietary waste heat conversion technology, which profitably converts waste heat generated from industry processes and other sources into clean energy, as well as its exclusive license to distribute high-performance LED lighting products in North America, Mexico, Latin America and the Caribbean.

ForceField Energy is operated by a highly experienced management team with numerous years of business development and public company experience in a high profile environment. Natan describes the backgrounds and qualifications of several key members of ForceField Energy management, as well as details his own experience as Chief Financial Officer of four listed U.S. public companies.

In his comprehensive review of the company, Natan also touches on ForceField Energy’s overall growth strategy and the recent significant progress made by the Company on several fronts.

About ForceField Energy Inc.

ForceField Energy is a global company whose products and solutions focus on renewable energy and improved energy efficiency. ForceField’s subsidiary, TransPacific Energy Inc. (“TPE”), has patented a technology which uses proprietary multiple component fluids that are environmentally sound, non-toxic and non-flammable. Custom formulated mixtures efficiently capture and convert heat directly from the heat source at temperatures ranging from 75° F to 950° F. TPE’s technology offers applications at broader temperature ranges than other energy recovery systems. TPE’s systems in certain applications reduce operating and maintenance costs thereby significantly improving return on capital expenditures, thus making the purchase of waste heat recovery systems which previously yielded nominal savings, economically viable. ForceField is the exclusive distributor in the U.S., Canada, Mexico, Latin America, and the Caribbean of Light Emitting Diode (“LED”) commercial lighting products and fixtures for a premier LED manufacturer, Lightsky. An LED is a semiconductor device which converts electricity into light. The LED light is considered “green” because of the absence of dangerous chemicals and an accompanying significant reduction in energy consumption depending on the application, from 50% to 70% of traditional lighting products.

ForceField is a distributor for PowerOneData International, Inc. a company that provides Advanced Metering Infrastructure and ASLM solutions to the international energy markets, reducing energy resource consumption and its negative impact on the environment and public health. ForceField is also a significant manufacturer and distributor of trichlorosilane (“TCS”) in China. TCS is a specialty chemical primarily used in the production of polysilicon, which is an essential raw material in the production of solar cells for PV panels that convert sunlight to electricity. TCS is considered to be the first product in the solar PV value chain before polysilicon, and is also the principal source of ultrapure silicon in the semiconductor industry. For additional information regarding ForceField Energy Inc. or Transpacific Energy, Inc., please visit the companies’ websites at www.ForceFieldenergy.com, www.transpacenergy.com, www.lightsky-led.com or contact Richard St-Julien at (212) 672-1786.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://www.MissionIR.com

To connect with MissionIR via Facebook, please visit http://www.Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://www.Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

Contact information

ForceField Energy Inc.
Richard ST Julien
212-672-1786
www.ForceFieldenergy.com

Mission Investor Relations
Sherri Franklin
404-941-8975
www.MissionIR.com

Wednesday, September 18th, 2013 Uncategorized Comments Off on (FNRG) MissionIR Features ForceField Energy CEO David Natan in Exclusive Interview

(SPSC) and Accellos, Breakthrough Supply Chain Solution for Microsoft Dynamics GP Market

Market Leaders Enable Automated Access to Largest Retail Enterprise Cloud Marketplace

MINNEAPOLIS and COLORADO SPRINGS, Colo., Sept. 17, 2013  — SPS Commerce, Inc. (Nasdaq:SPSC), a leader in enterprise retail cloud services, and Accellos, a leading provider of supply chain execution software solutions, today announced that they have partnered to deliver a fully integrated, turnkey supply chain management solution for the Microsoft Dynamics® GP market. The breakthrough enterprise cloud service changes the competitive landscape, enabling suppliers to seamlessly connect with more than 50,000 supply chain partners including retailers, distributors, vendors and logistics providers through a single connection from their Microsoft Dynamics® GP system to SPS’s Universal Network.

Driving Omni-Channel Efficiency

In a marketplace where e-commerce is dictating the tempo of change, retailers and suppliers require highly nimble and adaptable supply chain capabilities to respond instantly to changes in consumer demand and delivery preferences. Accellos and SPS Commerce bring these essential capabilities to the Microsoft Dynamics® GP community.

“SOG needed to integrate every trading partner in our supply chain with our Microsoft Dynamics® GP system to support our substantial growth,” said Nando Zucchi, Vice President of Sales & Marketing, SOG Specialty Knives & Tools. “With SPS and Accellos, we seamlessly automated our trading relationships with major drop-ship and traditional retailers including Amazon.com, Costco.com, Dick’s Sporting Goods, Wal-Mart and others within a few short weeks. This holiday season we will automate 1,750 transactions each week, saving our staff more than 60 hours of data entry every week. We are delighted by the solution and expertise provided by SPS and Accellos.”

Nimble Supply Chains are Connected

The enterprise cloud service for Microsoft Dynamics® GP was developed by Accellos using the SPS Commerce Retail Standard XML (RSX), a comprehensive data interchange format that enables frictionless expansion and growth of trading partner relationships. RSX works with all data formats (including EDI, XML, flat file and others), allowing suppliers to automatically connect with a greater percentage of their supply chain community. The cloud-based solution connects an organization’s Microsoft Dynamics® GP system to the SPS Universal Network, not only automating supply chain relationships with more than 50,000 trading partners worldwide with a single integration, but also providing automated connections to any future trading partners.

“The SPS Universal Network offers our customers access to the leading retail enterprise cloud service and dramatically expands the reach and power of their Microsoft Dynamics® GP solution,” said Chad Collins, General Manager and Chief Marketing Officer, Accellos. “This partnership is helping to transform our business as we continue to expand our leadership position in the market and create new opportunities with the thousands of retail organizations in SPS Commerce’s Universal Network.”

“Accellos brings a truly world class Microsoft Dynamics® GP solution to the market powered by the SPS Universal Network,” said Peter Zaballos, Vice President of Marketing, SPS Commerce. “Using the SPS Universal Network and our RSX standard, Accellos can provide its customers the nimble, responsive supply chain capabilities required to meet the needs of today’s rapidly evolving retail marketplace.”

The enterprise cloud service for Microsoft Dynamics® GP is immediately available from Accellos and SPS Commerce.

Retail executives will hear more about the new cloud solution from Accellos and SPS Commerce at The Business of Omni-Channel Retail event on October 8, 2013, in New York City.

About Accellos

Accellos is a global provider of software solutions specifically designed for the unique needs of logistics service providers and midsized businesses. Over 3,000 companies trust Accellos to be the technology backbone of their global supply chains. Accellos provides solutions for warehouse management systems (WMS), third party logistics (3PL), fleet management, transportation management systems (TMS), trading partner integration (EDI), automated barcode data collection, parcel shipping, transportation optimization and supply chain business intelligence. Accellos solutions are built on the AccellosOne platform, a modern technology platform featuring a user-friendly interface and simplified technical administration. For more information, email info@accellos.com or visit www.accellos.com.

About SPS Commerce

SPS Commerce perfects the power of your trading partner relationships with the industry’s most broadly adopted, enterprise retail cloud services platform. As a leader in on-demand supply chain management solutions, we provide prewired, proven integrations and comprehensive retail performance analytics to thousands of customers worldwide. With a singular focus on the retail marketplace, we revolutionized traditional EDI systems by developing a platform that enables highly cost-effective and reliable trading partner collaboration. SPS Commerce has achieved 50 consecutive quarters of revenue growth and is headquartered in Minneapolis. For additional information, please contact SPS Commerce at 866-245-8100 or visit www.spscommerce.com.

SPS COMMERCE, SPSCOMMERCE.NET, and RETAIL UNIVERSE are marks of SPS Commerce, Inc. and Registered in U.S. Patent and Trademark Office. INFINITE RETAIL POWER, SPS, SPS logo and others are further marks of SPS Commerce, Inc. These marks may be registered or otherwise protected in other countries.

SPS-C

CONTACT: Kay Rindels
         SPS Commerce
         866-245-8100
         krindels@spscommerce.com

         Kait Vinson
         Accellos
         719-433-7032
         Kait.Vinson@accellos.com
Tuesday, September 17th, 2013 Uncategorized Comments Off on (SPSC) and Accellos, Breakthrough Supply Chain Solution for Microsoft Dynamics GP Market

(AGEN) Positive Follow-on Phase 2 Results for Brain Cancer Vaccine

Agenus Inc. (NASDAQ: AGEN) today announced that a recent analysis from a Phase 2 trial in patients with newly diagnosed glioblastoma multiforme (GBM) treated with Prophage Series G-100 (HSPPC-96) in combination with the current standard of care (radiation and temozolomide) showed an almost 18 month median progression free survival (PFS), which represents a 160% increase versus current standard of care alone. This analysis confirms continuation of the positive trends from the Phase 2 HSPPC-96 newly diagnosed GBM trial first reported at the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in May 2013.

“These additional results from the Phase 2 trial of HSPPC-96 in patients with newly diagnosed GBM are extremely encouraging and certainly justify a definitive randomized study,” said Andrew T. Parsa, MD, PhD, Lead Clinical Investigator and Chair of Neurosurgery at Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine. “The patient-specificity and lack of toxicity, combined with patient selection to optimize immunotherapy efficacy, could position this vaccine as a break-through treatment for newly diagnosed GBM patients in the years ahead.”

Based on these findings, Agenus plans to hold an end of Phase 2 meeting with the US Food and Drug Administration to discuss a Phase 3 trial that could potentially lead to marketing approval of the HSPPC-96 vaccine as a treatment for patients with newly diagnosed GBM.

Phase 2 HSPPC-96 Update in Newly Diagnosed GBM Patients

The Phase 2 trial of HSPPC-96 in patients with newly diagnosed GBM includes 46 patients treated at eight centers across the US. Patients were treated with radiation and temozolomide as the standard of care in addition to HSPPC-96 vaccination. Analyses of data collected to date show a median PFS of 17.8 months with 63% of the patients progression free at twelve months and 20% progression free at 24 months. These results indicate considerable improvement when compared to patients treated with the standard of care (radiation plus temozolomide), which is 6.9 months.1

Median overall survival (OS), the primary endpoint of the trial, is 23.3 months and remains durable in patients treated with HSPPC-96. In this study, the 12 month survival rate is 85% with 50% of patients still alive and being followed, with many surviving beyond the 24 month study period. For the standard of care alone, median OS survival rate is 14.6 months.1

The Phase 2 recurrent and newly diagnosed trials are being sponsored by Dr. Parsa and are primarily supported through funding from the American Brain Tumor Association, Accelerated Brain Cancer Cure, National Brain Tumor Society, and National Cancer Institute Special Programs of Research Excellence. Dr. Parsa has not received any financial support or expense reimbursement for this work or for consulting activities on behalf of Agenus. He does not have an equity interest in Agenus or a financial relationship with the company.

About the Randomized HSPPC-96 ALLIANCE Trial in Recurrent GBM

In addition to the Phase 2 newly diagnosed GBM trial, the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) is supporting a study of the HSPPC-96 vaccine in a large, randomized Phase 2 trial in combination with bevacizumab (Avastin®) in patients with surgically resectable recurrent GBM. Patients have already been randomized into this trial and active recruitment is underway at multiple centers in the US. The study is being sponsored by the Alliance for Clinical Trials in Oncology (ALLIANCE), a cooperative group of the NCI. This trial is the largest brain tumor trial ever funded by the NCI and the largest vaccine study ever conducted with Avastin.

The ALLIANCE trial is investigating the potential benefits of treatment with a combination of HSPPC-96 and bevacizumab in a three-arm study of approximately 222 patients with surgically resectable recurrent GBM using a primary endpoint of overall survival. The study will compare efficacy of the HSPPC-96 vaccine administered with bevacizumab either concomitantly or at progression, versus treatment with bevacizumab alone. This study design is supported in part by previous research indicating a potential synergistic effect between the mechanisms of action behind both HSPPC-96 and bevacizumab. For additional information about the ALLIANCE trial visit ClinicalTrials.gov using Identifier NCT01814813.

The ALLIANCE is composed of three NCI funded cooperative groups (American College of Surgeons Oncology Group [ACOSOG], Cancer and Leukemia Group B [CALGB], and North Central Cancer Treatment Group [NCCTG]). These three groups have been integrated in an effort to develop and conduct more efficient clinical research studies to bring clinical trial results to patients more quickly.

In addition to the newly diagnosed GBM study in Prophage Series G-100 and the ALLIANCE trial, a Phase 2 study testing the Prophage Series G-200 in patients with recurrent glioma has been completed. Agenus expects the final trial results of this study to be published in a scientific journal in 2014.

About Glioblastoma Multiforme (GBM)

The incidence rates of primary malignant brain and central nervous system cancers have increased over the last three decades.2 The American Cancer Society estimates that more than 23,000 malignant tumors of the brain or spinal cord will be diagnosed during 2013 in the US, and that more than 14,000 people will die from these tumors. 3 GBM is the most common primary malignant brain tumor and accounts for the majority of diagnoses. It has been associated with a particularly poor prognosis, with survival rates at one and five years equaling 33.7% and 4.5%, respectively.4 The current standard of care for patients with newly diagnosed GBM is surgical resection followed by fractionated external beam radiotherapy and systemic temozolomide5 resulting in a median OS of 14.6 months6 based on data from a randomized Phase 3 trial. Although this treatment can prolong survival, it is not curative and the vast majority of patients with GBM experience recurrent disease, with a median time to recurrence of seven months.7 Currently, there is no standard treatment for patients with recurrent GBM, although additional surgery, chemotherapy (i.e., CCNU, temozolomide), bevacizumab, and radiotherapy are used.

About the Prophage Series (HSPPC-96) Cancer Vaccines

Prophage Series cancer vaccines are autologous therapies derived from cells extracted from the patient’s tumor. As a result, Prophage Series vaccines contain a precise antigenic ‘fingerprint’ of a patient’s particular cancer and are designed to reprogram the body’s immune system to target only cells bearing this fingerprint, reducing the risk that powerful anti-cancer agents will target healthy tissue and cause debilitating side effects often associated with chemotherapy and radiation therapy. The Prophage Series G vaccines are currently being studied in two different settings of glioblastoma: newly diagnosed and recurrent disease.

About Agenus

Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Between Agenus and its partners, 23 programs are in clinical development. For more information, please visit www.agenusbio.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+.

Forward-Looking Statement

This press release contains forward-looking statements, including statements regarding clinical trial activities, the publication of data, and the potential application of the Company’s technologies and product candidates in the prevention and treatment of diseases. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the period ended June 30, 2013. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Agenus undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Agenus’ business is subject to substantial risks and uncertainties, including those identified above. When evaluating Agenus’ business and securities, investors should give careful consideration to these risks and uncertainties.

References

1. Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N

Engl J Med, 2005. 352(10): p. 987-96.

2. Maher EA, McKee AC. In: Atlas of diagnostic oncology. 3. Skarin AT, Canellos GP, editor. London: Elsevier Science; 2003. Neoplasms of the central nervous system; pp. 5–10.

3. http://www.cancer.gov/cancertopics/pdq/treatment/adultbrain/HealthProfessional/page1

4. Central Brain Tumor Registry of the United States (CBTRUS) 2010 CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2006. http://www.cbtrus.org/reports/reports.html

5. National Comprehensive Cancer Network clinical practice guidelines in oncology-central nervous system cancers. v.1.2010.

6. Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N

Engl J Med, 2005. 352(10): p. 987-96.

7. Wen PY, DeAngelis LM. Chemotherapy for low-grade gliomas: emerging consensus on its benefits. Neurology. 2007;68(21):1762–1763. doi: 10.1212/01.wnl.0000266866.13748.a9.

Avastin is a registered trademark of Genentech.

Tuesday, September 17th, 2013 Uncategorized Comments Off on (AGEN) Positive Follow-on Phase 2 Results for Brain Cancer Vaccine

(FU) Secures Music Distribution Rights from Top 3 Chinese Mobile Providers

FAB Universal (NYSE MKT:FU), a worldwide distributor of digital media and entertainment, today announced that it has signed agreements to distribute its copyright-protected digital music content through China Unicom, China Mobile and China Telecom, the top three providers of mobile phone services in China.

Expanding our distribution platform and increasing the quantity and variety of our content are the twin growth engines at FAB. With these agreements, we are now adding a mobile phone channel to FAB’s distribution platform and further leveraging both our exclusive and acquired copy-right protected digital music content. As we supply our digital music content directly to the subscribers of the top three mobile phone service providers in China, we will also reach new customers for our catalog of FAB-branded digital media and entertainment content,” said Chris Spencer, chief executive officer.

About FAB Universal Corp.

FAB Universal Corp. is a global leader in digital media entertainment sales and distribution. FAB delivers media to its customers worldwide through Intelligent Kiosks, Retail Stores and Franchises, and online through Apple iTunes and Google Android. We distribute billions of movie, music, podcast, TV show and other digital files to consumers in 240 countries through three business units: Digital Media Services, Retail Media Sales and Wholesale Media Distribution. Sales of digital media are generated through the kiosks networks, subscription sales for mobile devices, smartphone Apps and Netflix-like subscription models. In 2011, we distributed billions of downloads of copyrighted music, video games, ringtones, ebooks, movies and podcasts to over 50 million people worldwide through iPods, iPhones, iPads, iTunes, Blackberrys, Windows Phones, Androids and many other devices and destinations. We are a publicly held, Pittsburgh based company with thousands of shareholders and a world-class team. Visit us on the web at www.fabuniversal.com, email us at contact@fabuniversal.com.

Legal Notice

Legal Notice Regarding Forward-Looking Statements: “Forward-looking Statements” as defined in the Private Securities litigation Reform Act of 1995 may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. We disclaim any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with changes in general economic and business conditions, actions of our competitors, the extent to which we are able to develop new services and markets for our services, the time and expense involved in such development activities, the level of demand and market acceptance of our services or changes in our business strategies.

Tuesday, September 17th, 2013 Uncategorized Comments Off on (FU) Secures Music Distribution Rights from Top 3 Chinese Mobile Providers

(PTOO) Announces Strong Financial Results for Fiscal 2013 Second Quarter

PHOENIX, AZ–(Sep 17, 2013) –  PITOOEY!,™ Inc. (OTCBB: PTOO), a complete digital marketing agency, today announces gross revenues of $108,788 for its FY 2013 second quarter, ended June 30, 2013, compared to $67,935 for the prior quarter, ending March 31, 2013. This represents an increase of $40,853, or 60 percent (60%), quarter-over-quarter.

The Company’s wholly-owned subsidiary, Choice One Mobile, Inc., is primarily responsible for the rapid growth in sales, which resultantly increased gross profit approximately 42 percent (42%), or $26,092, during the second quarter of FY 2013 compared to the first quarter of FY 2013.

PITOOEY! anticipates further gains in revenue, as a result of Choice One Mobile recently launching the C1M affiliate program. This program will enable agents of credit card processing companies to instantly generate an additional revenue stream by selling C1M’s mobile and social media services to existing merchant clientele. The benefits to Choice One Mobile include greater market penetration, with lower overhead and customer acquisition costs. The Company also began negotiations with several large credit card processing companies and independent sales organizations.

CFO, Patrick Deparini, commented: “A refined sales approach contributed to our second quarter results, as did continued operational improvements. We are continuously refining our services to maximize revenue, while providing a rate of return to business customers greater than they would be able to obtain by advertising or marketing through traditional media outlets.”

About PITOOEY!™, Inc.

PITOOEY!, Inc., via its wholly owned subsidiaries PITOOEY! Mobile, Inc. and Choice One Mobile, Inc., is a complete digital marketing agency offering businesses unique service packages based on the client’s requests. These requests, including the type of following or reach desired, are filtered through the Company’s subsidiaries to provide the perfect fit.

For more information, please visit:
www.PitooeyInc.com
www.Pitooey.com
www.ChoiceOneMobile.com

Safe Harbor
This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of PITOOEY!, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond PITOOEY!, Inc.’s ability to control and their actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in PITOOEY!, Inc.’s filings with the Securities and Exchange Commission.

Contact:

PITOOEY!, Inc.
Corporate Communications
Phoenix, AZ
www.Pitooey.com
480-999-6025
PTOO@MissionIR.com

Mission Investor Relations (MissionIR)
Investor Relations
Atlanta, GA
www.MissionIR.com
404-941-8975 Direct
Investors@MissionIR.com

Tuesday, September 17th, 2013 Uncategorized Comments Off on (PTOO) Announces Strong Financial Results for Fiscal 2013 Second Quarter

(WILN) and Alcatel-Lucent Enter Into License Agreement, Settle All Litigations

OTTAWA, CANADA–(Marketwired – Sept. 16, 2013) – Wi-LAN Inc. (“WiLAN” or the “Company”) (TSX:WIN) (NASDAQ:WILN) today announced that WiLAN has entered into a patent license agreement and settled all pending patent litigations with Alcatel-Lucent USA Inc. (“Alcatel-Lucent”). Under the license agreement, Alcatel-Lucent has been granted a multi-year license to certain WiLAN patents related to wireless products in consideration for which Alcatel-Lucent will make a series of payments to WiLAN throughout the term of the license. The parties have agreed to settle all pending litigations in the United States District Courts for the Southern District of Florida and the Eastern District of Texas involving CDMA, 3GPP, HSPA, Wi-Fi and LTE technologies.

Under a separate patent acquisition agreement between the parties also announced today, WiLAN will acquire from Alcatel-Lucent a portfolio of patents and pending applications related to current and next-generation wireless technologies with broad worldwide patent coverage. All other terms and conditions of the license and acquisition agreements are confidential.

“We are very pleased to have reached a business resolution to our licensing discussions with Alcatel-Lucent, and to add them to our list of licensees,” said Jim Skippen, President & CEO. “Alcatel-Lucent’s long history of fundamental technology development and strong IP protection has enabled it to become a leader in the wireless industry. The addition of Alcatel-Lucent patents and applications to our wireless portfolio continues to expand the value we are able to offer to our existing and future licensees.”

About WiLAN

WiLAN, founded in 1992, is a leading technology innovation and licensing company. WiLAN has licensed its intellectual property to over 270 companies worldwide. Inventions in our portfolio have been licensed by companies that manufacture or sell a wide range of communication and consumer electronics products including 3G and 4G handsets, Wi-Fi-enabled laptops, Wi-Fi and broadband routers, xDSL infrastructure equipment, cellular base stations and digital TV receivers. WiLAN has a large and growing portfolio of more than 3,000 issued or pending patents. For more information: www.wilan.com.

Forward-looking Information

This news release contains forward-looking statements and forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other United States and Canadian securities laws. The phrases “will make”, “throughout”, “to settle”, “to begin”, “will acquire”, “to be”, “to expand”, “to offer” and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements and forward-looking information are based on estimates and assumptions made by WiLAN in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that WiLAN believes are appropriate in the circumstances. Many factors could cause WiLAN’s actual performance or achievements to differ materially from those expressed or implied by the forward-looking statements or forward-looking information. Such factors include, without limitation, the risks described in WiLAN’s March 7, 2013 annual information form for the year ended December 31, 2012 (the “AIF”). Copies of the AIF may be obtained at www.sedar.com or www.sec.gov. WiLAN recommends that readers review and consider all of these risk factors and notes that readers should not place undue reliance on any of WiLAN’s forward-looking statements. WiLAN has no intention and undertakes no obligation to update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

All trademarks and brands mentioned in this release are the property of their respective owners.

Tyler Burns
Director, Investor Relations
O: 613-688-4330
C: 613-697-0367
tburns@wilan.com
www.wilan.com

Monday, September 16th, 2013 Uncategorized Comments Off on (WILN) and Alcatel-Lucent Enter Into License Agreement, Settle All Litigations

(QTWW) Signs Definitive Agreements for $11M Private Placement

LAKE FOREST, Calif., Sept. 16, 2013 — Quantum Fuel Systems Technologies Worldwide, Inc. (Nasdaq: QTWW) (the “Company”), a global leader in natural gas storage systems, integration and vehicle system technologies, announced today that it has entered into definitive agreements with certain accredited investors for a private placement of 2% senior secured convertible notes in the cumulative principal amount of $11.0 million and warrants (the “Offering”).  Mr. Kevin Douglas of Larkspur, California, led the transaction with an investment of $10.0 million.  The terms of the offering satisfy the requirements of NASDAQ to be considered an above market value transaction and as such, members of the Company’s management team and board of directors also participated in the offering, including W. Brian Olson, the Company’s Chief Executive Officer and Bradley Timon, the Company’s Chief Financial Officer. The closing of the Offering is expected to occur on or around September 18, 2013.  The Company will use approximately $7.3 million of the proceeds to retire bridge debt that matures over the next 45 days.  The remainder will be used for general working capital.  Craig-Hallum Capital Group LLC acted as the Company’s placement agent.

The principal and interest due under the notes is payable on the fifth anniversary of the closing, subject to the investors’ put right that may be exercised during the thirty day period following the third anniversary of the closing.  Subject to certain beneficial ownership limitations, the notes are convertible at any time into shares of the Company’s common stock at a conversion price per share of $2.3824, which represents a 3.6% premium to the previous closing price for a share of the Company’s common stock.  The notes are secured by a second lien position on substantially all of the assets of the Company’s continuing operations.

The investors received warrants to purchase up to 3,411,235 shares of the Company’s common stock at an exercise price of $2.30 per share.  The warrants cannot be exercised for six months following the closing and expire in March 2019.

Pursuant to the terms of the definitive agreements, Mr. Douglas was given the right to appoint one individual to serve on the Company’s board of directors for as long as any of the convertible notes remain outstanding.

The full terms of the transaction will be filed with the Securities and Exchange Commission in a Current Report on Form 8-K on or around September 17, 2013.

The securities are being offered and sold solely to accredited investors on a private placement basis.  The Company has agreed to file a registration statement covering resales of the shares underlying the notes and warrants within 90 days following the closing.

This press release does not and shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration under the securities laws of any state or jurisdiction.

About Quantum

Quantum Fuel Systems Technologies Worldwide, Inc. is a leader in the innovation, development and production of natural gas fuel storage systems and the integration of vehicle system technologies including engine and vehicle control systems and drivetrains. Quantum produces one of the most innovative, advanced, and light‐weight compressed natural gas storage tanks in the world and supplies these tanks, in addition to fully‐integrated natural gas storage systems, to truck and automotive OEMs and aftermarket and OEM truck integrators. Quantum provides low emission and fast‐to‐market solutions to support the integration and production of natural gas fuel and storage systems, hybrid, fuel cell, and specialty vehicles, as well as modular, transportable hydrogen refueling stations. Quantum is headquartered in Lake Forest, California, and has operations and affiliations in the United States, Canada, and India.

More information about the products and services of Quantum can be found at http://www.qtww.com/or you may contact:

Brion D. Tanous
Principal
CleanTech IR, Inc.
Email: btanous@cleantechir.com
310‐541‐6824

Monday, September 16th, 2013 Uncategorized Comments Off on (QTWW) Signs Definitive Agreements for $11M Private Placement

(NBY) Positive Phase 2 Clinical Study of Auriclosene Urinary Catheter Blockage

Primary Endpoints Achieved Showing Statistically Significant and Clinically Meaningful Benefits for Patients with Long-Term Indwelling Catheters Results Pave the Way for Phase 3 Pivotal Studies

NovaBay Pharmaceuticals, Inc., an advanced clinical-stage biopharmaceutical company developing anti-microbial products, today announced positive top-line results from its recently completed Phase 2 clinical study CL1001 for auriclosene (NVC-422) to prevent urinary catheter blockage and encrustation (UCBE) of indwelling urinary catheters. The results of the study show that NovaBay’s auriclosene-based irrigation solution has demonstrated the ability to mitigate an important medical problem, cut healthcare costs, and improve the quality of life for tens of thousands of patients in the U.S. alone.

Study Results

This three part study utilized randomized double-blinded, placebo-controlled crossover design, where patients served as their own control and received both placebo and auriclosene. The study enrolled 67 subjects with chronic indwelling transurethral or suprapubic urinary catheters. There were a total of 125 treated catheters: 62 in the auriclosene arm and 63 in saline arm. In Part 3 of the study, which represents the clinical paradigm of four weeks of catheter duration use, subjects’ catheters were irrigated twice weekly with a solution of either 0.2% auriclosene or saline for a total of eight treatments over four weeks, followed by a washout period and a similar cross-over treatment.

The top-line results show auriclosene was effective at reducing the degree of catheter encrustation and maintaining the catheter patency over the course of the study. Overall, the auriclosene irrigation solution reduced the average encrustation at the time of catheter removal from 77 percent encrusted (saline arm) to 22 percent encrusted (auriclosene arm). Importantly, a within-subject comparison for the degree of encrustation showed that the auriclosene arm demonstrated a statistically significant reduction (p = 0.005) in the degree of encrustation. Complete catheter blockage was not observed in any of the auriclosene-treated catheters, but was observed in 64 percent of the catheters treated with saline (p = 0.0004). Fifty percent of the saline-treated catheters had to be removed early because of laboratory-confirmed blockage, compared to none of the auriclosene-treated catheters. The drug was well tolerated; there were no treatment-related serious adverse events and only transient manageable adverse events in both treatment arms.

Because of spinal cord injuries, multiple sclerosis, strokes, or other neurogenic bladder conditions, an estimated 100,000 patients in the U.S. have indwelling catheters and episodically suffer from blockage and encrustation. In these patients catheters repeatedly become coated with bacteria and bacterial biofilm, which may produce localized crystal deposits and may build up and block the catheter.

Major medical problems can follow, as explained by Todd A. Linsenmeyer, M.D., Director of Urology at Kessler Institute for Rehabilitation, and a principal investigator in the completed Phase 2 study: “The severe consequences of urinary catheter blockage and encrustation are often underappreciated. Catheter blockage can result not only in urinary tract infections and socially embarrassing urine leakage around the catheter, but also frequent use of emergency services and, in those with high level spinal cord injuries, potentially life-threatening autonomic dysreflexia.”

Video: NovaBay Pharmaceuticals’ Urinary Catheter Blockage and Encrustation Solution Provides Hope for Spinal Cord Injury Patients and Other Patients with Indwelling Catheters.

https://www.youtube.com/watch?v=hHRnlYEHgmA

Currently, treatment options for these patients are minimally effective. Preventative treatment such as flushing catheters with saline solution, merely provides a partial mechanical dislodging of encrustation. Many patients have no alternative but to change catheters frequently before the encrustation becomes severe. This study demonstrates that NovaBay’s innovation to irrigate the catheter only two times per week with a formulation containing the company’s broad-spectrum anti-microbial product, auriclosene (NVC-422), is a substantial improvement for these patients. Auriclosene is a stable version of natural anti-microbial chemicals produced by white blood cells to inactivate and destroy microbial invaders. These proprietary anti-microbial chemicals maintain catheter patency by killing the bacteria and disrupting the biofilm that is responsible for causing the blockage.

“We are excited to see that auriclosene may dramatically reduce the problems of unpredictable early catheter blockage which may lead to uncontrolled autonomic dysreflexia and significant cost to the healthcare system,” said Ron Najafi, Ph.D., Chairman and Chief Executive Officer of NovaBay. “This study confirms our belief that catheter irrigation with auriclosene can make a substantial difference in the lives of patients with long-term indwelling catheters.”

Based on these study results, the Company plans to continue discussions with the FDA and move toward registration. A catheter irrigation solution that significantly reduces catheter blockage and encrustation could greatly reduce the estimated $1 billion spent annually to help patients with indwelling urinary catheters deal with costs attributable to this debilitating condition. Such a product would also improve the quality of patients’ lives by reducing the consequences of unexpected catheter blockages.

Auriclosene and the Management of UCBE

UCBE is caused by the build-up of calcium and magnesium crystals in the lumen and inlet of catheters, which in turn, is most often caused by gram-negative bacteria that secrete a chemical called urease. The condition requires catheters to be changed frequently. It can also lead to urinary tract infections (UTIs), incontinence due to the leakage of urine around the outside of clogged catheters and, in certain patients, severe and life-threatening episodes of uncontrolled autonomic dysreflexia. Autonomic dysreflexia (AD) is a reaction of the autonomic (involuntary) nervous system to noxious stimuli that occurs in individuals with high level spinal cord injuries. It may result in a number of problems such as profuse sweating, flushing and an intense, pounding headache. However, the most dangerous problem is a sudden severe increase in blood pressure. The most frequent causes of AD in those with an indwelling catheter are bladder over distention and catheter blockage. The AD continues until the blocked catheter is changed. If blockage is not dealt with immediately, the increased blood pressure could lead to a life threatening stroke or cardiovascular event.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics

NovaBay Pharmaceuticals is an advanced clinical-stage biopharmaceutical company focused on addressing the large unmet therapeutic needs of the global, topical anti-infective market with its Aganocide compounds, led by auriclosene. Auriclosene is a new chemical entity invented by NovaBay and has a broad spectrum of activity against bacteria, viruses and fungi. Aganocide compounds are based on the human body’s natural immune system and the molecules involved in combating infections. Bacterial resistance to Aganocides is highly unlikely, as demonstrated in in vitro studies. Once pathogens penetrate the body’s primary defense, the next line of defense is provided by the white blood cells. NovaBay has focused on understanding these molecules generated by the white blood cells and finding ways, by chemical modification, to allow them to be developed as therapeutic products with the potential to treat a wide range of local, non-systemic infections. As Aganocides® begin to supplement and thereby reduce the usage of classic topical antibiotics, they will help slow the rise of antibiotic resistance.

Forward-Looking Statements

This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the expected timing of enrollment and commencement of clinical trials, expected timing of announcement of results of clinical studies, and expected future financial results. The words “continued,” “expected,” “will be,” “believe”, “expect”, “anticipate”, “would,” “planning” and other words (and all variations of these words that imply future events), identify these statements as forward looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. These risks and others are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Stay informed on NovaBay’s progress:

Like us on Facebook

Follow us on Twitter

Connect with NovaBay on LinkedIn

Join us on Google+

Visit NovaBay’s Website

Monday, September 16th, 2013 Uncategorized Comments Off on (NBY) Positive Phase 2 Clinical Study of Auriclosene Urinary Catheter Blockage

(FNRG) Announces Engagement of MissionIR Investor Relations Services

ATLANTA, GA–(Sep 16, 2013) – ForceField Energy Inc. (OTCQB: FNRG) (the “Company”) today announces that they have engaged the investor relations services of MissionIR. Through a network of investor-oriented sites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital as well as improve shareholder value.

“ForceField Energy has an exciting business model targeting two of the largest and fastest-growing areas of the global renewable energy space,” stated Sherri Franklin, Director of Marketing at MissionIR. “The Company is well positioned in both sectors and has an experienced management team in place to fully execute its growth strategy.”

David Natan, CEO of ForceField Energy, stated, “Engagement of a full-service investor relations firm to develop and implement a strategic investor relations campaign is a key part of our overall strategy to achieve short-term and long-term goals. MissionIR is providing a much needed service in the small-cap markets.”

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. Through a full suite of investor relations and consultancy services, we help public companies develop and execute a strategic investor awareness plan as we’ve done for hundreds of others. Whether it’s capital raising, increasing awareness among the financial community, or enhancing corporate communications, we offer a variety of solutions to meet the objectives of our clients.

For more information, visit www.MissionIR.com

About ForceField Energy Inc.

ForceField Energy is a global company whose products and solutions focus on renewable energy and improved energy efficiency. ForceField’s subsidiary, TransPacific Energy Inc. (“TPE”), has patented a technology which uses proprietary multiple component fluids that are environmentally sound, non-toxic and non-flammable. Custom formulated mixtures efficiently capture and convert heat directly from the heat source at temperatures ranging from 75° F to 950° F. TPE’s technology offers applications at broader temperature ranges than other energy recovery systems. TPE’s systems in certain applications reduce operating and maintenance costs thereby significantly improving return on capital expenditures, thus making the purchase of waste heat recovery systems which previously yielded nominal savings, economically viable. ForceField is the exclusive distributor in the U.S., Canada, Mexico, Latin America, and the Caribbean of Light Emitting Diode (“LED”) commercial lighting products and fixtures for a premier LED manufacturer, Lightsky. An LED is a semiconductor device which converts electricity into light. The LED light is considered “green” because of the absence of dangerous chemicals and an accompanying significant reduction in energy consumption depending on the application, from 50% to 70% of traditional lighting products.

ForceField is a distributor for PowerOneData International, Inc. a company that provides Advanced Metering Infrastructure and ASLM solutions to the international energy markets, reducing energy resource consumption and its negative impact on the environment and public health. ForceField is also a significant manufacturer and distributor of trichlorosilane (“TCS”) in China. TCS is a specialty chemical primarily used in the production of polysilicon, which is an essential raw material in the production of solar cells for PV panels that convert sunlight to electricity. TCS is considered to be the first product in the solar PV value chain before polysilicon, and is also the principal source of ultrapure silicon in the semiconductor industry.

For more information, visit www.ForceFieldenergy.com

Forward-Looking Statements

This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information included in this Press Release including such forward-looking statements.

Contact:

Mission Investor Relations
Sherri Franklin
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Monday, September 16th, 2013 Uncategorized Comments Off on (FNRG) Announces Engagement of MissionIR Investor Relations Services

(CXM) LifeAgain, First Life Insurance Program For Men With Prostate Cancer

SAN DIEGO, Sept. 16, 2013 — Cardium Therapeutics (NYSE MKT: CXM) today announced that LifeAgain™ Insurance Solutions Inc., a wholly-owned subsidiary in Cardium’s investment portfolio, and AgencyONE, its commercialization partner, have entered into agreements to market and sell term life insurance issued by Symetra Life Insurance Company under LifeAgain’s BlueMetric Select™ term life insurance program for men with active localized prostate cancer.  The BlueMetric Select program was developed based on LifeAgain’s Advanced Medical Data Analytics Platform Technology (ADAPT™). This new life insurance program (www.lifeagain.com) is expected to be available in all 50 states.

Prostate cancer is one of the most prevalent forms of cancer in the United States. Currently, men with elevated prostate-specific antigen (PSA) scores and active localized prostate cancer usually are considered uninsurable based on traditional underwriting standards.  LifeAgain’s BlueMetric Select program was specifically designed to assist life insurance companies to provide eligible men with term life insurance coverage following a cancer diagnosis or upon the completion of a prostate cancer surgery, without the traditional multi-year waiting periods and additional medical re-qualifications generally required by most life insurance companies.

LifeAgain’s proprietary Advanced Medical Data Analytics Platform Technology enables a scalable, actuarial-based risk assessment based on a diagnostic histological biopsy or a prostate cancer surgery.  Together with an applicant’s overall health, these factors may be used to support favorable underwriting decisions and to establish appropriate premium pricing based on the level of prostate cancer progression of each applicant.

The BlueMetric Select program has been designed for men aged 45-65, who are in otherwise good health and who have low- to medium-risk active localized prostate cancer, which has been confirmed by a recent biopsy, and for men who have recently completed prostate cancer surgery. This program seeks to provide term life insurance coverage and may include an automatic renewal option (following the initial ten-year term), the right to convert into universal life insurance, and an accelerated benefit in the event of a terminal illness. The BlueMetric Select Program is designed to offer substantial coverage levels, ranging from $100,000 to $1,000,000, without waiting periods, so an individual can begin the application process on the day of his prostate cancer diagnosis, or immediately following completion of prostate cancer surgery.  Additional information about the BlueMetric Select Program is available at www.lifeagain.com/wp-content/pdfs/symetra-level-term-fact-sheet.pdf.

“The American Cancer Society reports that there are more than 2.5 million men in the United States who have been diagnosed with prostate cancer.  Prostate cancer affects 1 in 6 men in the U.S., and over the next 10 years more than 8 million men under the age of 64 are expected to be diagnosed with an elevated PSA score. In 2013, more than 238,000 men will be diagnosed with prostate cancer and nearly 100,000 men will undergo prostate cancer surgery.  Our new BlueMetric Select program provides men with a life insurance option that they may not otherwise have as they manage their personalized prostate cancer journey that will last a lifetime, that may include ‘watchful waiting’ and ‘active surveillance,’ after re-evaluating their families’ life insurance needs in response to their prostate cancer diagnosis,” said Christopher J. Reinhard, Chairman and CEO of Cardium.

“We are pioneers in assisting life insurance companies in developing ‘survivable risk’ life insurance and believe that the introduction of LifeAgain’s BlueMetric Select program represents an important step forward for cancer patients, cancer survivors and their families, as well as the life insurance industry.  As a result, we will seek to advance the BlueMetric Select program into international markets and expand our Advanced Medical Data Analytics Platform Technology into other medical indications, first in the U.S. market and then internationally,” Reinhard said.

Over the past decades, medical advancements, improved early diagnosis and curative therapies, have transformed certain serious life-threatening diseases into managed conditions with significantly improved prognosis and quantifiable mortality risk.  The National Cancer Institute reports that there are nearly 12 million cancer survivors in the U.S., up from only 3 million in the early 1970s, and that almost 5 million survivors received their cancer diagnosis within the past 10 years. This represents millions of highly motivated individuals who may seek life insurance as part of their personal and family planning, and yet life insurance is often unavailable for patients diagnosed with cancer unless and until they can effectively demonstrate that their cancer has been cured. LifeAgain’s advanced medical data analytics offers significant opportunities to develop life insurance products that such patients need, offering new and innovative solutions for the life insurance industry.

LifeAgain’s Business Model
Under the agreements, term life insurance for men with localized prostate cancer will be exclusively marketed and sold nationwide by LifeAgain in collaboration with its commercialization partner AgencyONE, a national life insurance broker general agency (BGA).  LifeAgain is licensed as a life insurance agency in most states and contracted with Symetra Life Insurance Company (“Symetra”) to become an agent that can sell that Company’s life insurance.   Remuneration paid to LifeAgain by Symetra would be in the form of commissions for the sale of term life insurance policies.

LifeAgain would receive remuneration from direct sales of term life insurance through online applications, as well as through sales by established life insurance agents, brokers and financial advisors who may contract with LifeAgain on a nationwide basis.  LifeAgain estimates that annually there may be perhaps 400,000 men eligible to participate in the BlueMetric Select program in the United States.

Following the launch of the BlueMetric Select program for men with prostate cancer in the United States, LifeAgain expects to introduce the program into select European and other markets with local or regional commercialization partners as well as potentially non-domestic insurance carriers, and to develop and partner additional survivable-risk programs for the U.S. and international markets.

About AgencyONE
AgencyONE, a premier full-service life insurance brokerage general agency (BGA) located in Bethesda, Md., will be the sole BGA providing insurance industry expertise, and case management services for LifeAgain’s BlueMetric Select.  As one of the nation’s leading BGAs, AgencyONE has earned a solid reputation for outstanding exceptional service and innovative life insurance advanced planning. AgencyONE provides advanced planning solutions and expertise for emerging and affluent producers nationwide.  The long-standing relationships AgencyONE has established with insurance carriers, along with proficient underwriting knowledge, enables the company to deliver consistently competitive solutions and financial strategies to its producers and their clients.  AgencyONE specializes in impaired risk insurance coverage and dependably delivers the successful placement of significant life insurance policies in this challenging market.    Additional information is available at www.agencyone.net.

About LifeAgain
LifeAgain Insurance Solutions, Inc. is an advanced medical data analytics business and life insurance agency that is focused on the development, marketing and sale of “survivable risk” term life insurance programs for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards.  Working in cooperation with large and established life insurance companies, LifeAgain uses new actuarial methods, and scientific and medical data-driven insights to design life insurance solutions for those who may otherwise not be able to obtain coverage.  LifeAgain’s initial focus is on the development, marketing and sale of survivable risk life insurance for men with active localized prostate cancer.  LifeAgain plans to develop additional new and innovative life insurance solutions for men and women with other medical conditions.  Additional information is available at www.lifeagain.com.

About Cardium
Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium has four private company  business units in its medical opportunities portfolio: (1) Angionetics Biologics, which includes Cardium’s late-stage DNA-based Generx® cardiovascular biologic product candidate; (2) Activation Therapeutics, which includes the Company’s regenerative medicine wound healing technology platform, including its Excellagen® advanced wound care product; (3) To Go Brands®, which includes the Company’s health sciences and nutraceutical business; and (4) LifeAgain™ Insurance Solutions, Inc. which is focused on building the Company’s medical data analytics platform technology and selling term life insurance.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. For more information, visit www.cardiumthx.com.

About Symetra
Symetra Life Insurance Company is a subsidiary of Symetra Financial Corporation, a diversified financial services company based in Bellevue, Washington.  In business since 1957, Symetra provides employee benefits, annuities and life insurance through a national network of benefit consultants, financial institutions, and independent agents and advisers.  For more information, visit www.symetra.com.

Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there is no assurance that Cardium’s business unit, LifeAgain Insurance Solutions, Inc. and its partners, including AgencyONE  will successfully sell  “survivable risk” term life insurance policies  for cancer survivors or others with medical conditions, or that a market exists for such policies, or that life insurance companies will be able to offer such policies in such a market at affordable premium rates; that Cardium’s methods for data analytics and its LifeAgain business platform and products will be protectable and competitively useful, and will not be deemed to infringe on the rights of others; that the sales of survivable risk life insurance will generate substantial revenues for the Company; that clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the Company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that the Company will not be adversely affected by risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2013 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics®, Generx®, Excellagen®, LifeAgain™, BlueMetric™, Decision Rule Adaption™, ADAPT™, Angionetics Biologics, Activation Therapeutics are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.  To Go Brands®,  High Octane®, Green Tea Energy Fusion™, Acai Natural Energy Boost™, Greens to Go®, Extreme Berries to Go®, Healthy Belly®, VitaRocks®, Smoothie Complete®, Trim Green Coffee Bean™, and Trim Energy®, are trademarks of To Go Brands, Inc.  Other trademarks belong to their respective owners.

Insurance products are offered through LifeAgain, a licensed insurance agency. Insurance products are issued by Symetra Life Insurance Company, 777 108th Avenue NE, Suite 1200, Bellevue, WA 98004 and are not available in all U.S. states or any U.S. territory.  Symetra Life Insurance Company and the other subsidiaries under Symetra Financial Corporation are not affiliated with LifeAgain.

Monday, September 16th, 2013 Uncategorized Comments Off on (CXM) LifeAgain, First Life Insurance Program For Men With Prostate Cancer

(ENOC) VP Product Strategy and Tech Makes Boston Business Journal 40 Under 40

BOSTON, Sept. 13, 2013 — EnerNOC, Inc. (Nasdaq:ENOC), a leading provider of energy intelligence software, today announced that Micah Remley, EnerNOC’s Vice President of Product Strategy and Technology, has been named to Boston Business Journal’s 2013 “40 Under 40” List, an honor that recognizes “Boston’s best and brightest young professionals.” This year’s honorees were chosen by a panel of editors based on their influence on local business and industry, driving the overall health of the Boston economy. Volunteer work and other forms of philanthropy were also factored into the selection process.

“EnerNOC is helping to change the way the world uses energy through software-based tools and analytics, and it is exciting to be a part of that transformation. This award is really more of a recognition of our team’s collective efforts to change the status quo of energy management than it is an individual honor,” said Remley.

“Micah truly embodies EnerNOC’s culture of hiring ‘bright, relentless, and good’ people. He is committed to everything he does inside and outside of work, bringing an energy and passion that is hard to rival,” said Tim Healy, Chairman and CEO of EnerNOC.

Prior to his role as VP of Product Strategy and Technology, Micah served as EnerNOC’s Vice President of Operations where he managed an operations team of over 200 people responsible for executing thousands of megawatts of demand response dispatches every year. He was also a key driver in setting the strategic course for EnerNOC’s big data initiative, based on the collection of billions of energy data points to enable better energy management decision making by commercial, institutional, and industrial energy users.

Outside of work, Remley is an avid endurance sports participant and dedicated bike commuter. He is a past member of the Board of Directors of the Washington Trails Association, which protects hiking trails and wild lands, and promotes hiking as a healthy way to connect to the outdoors. He currently volunteers for Lincoln Youth Soccer, and coaches two youth soccer teams.

About EnerNOC

EnerNOC (Nasdaq:ENOC) is a leading provider of energy intelligence software and related solutions. EnerNOC unlocks the full value of energy management for utility and commercial, institutional, and industrial (C&I) customers by delivering a comprehensive suite of demand-side management services that reduce real-time demand for electricity, increase energy efficiency, improve energy supply transparency in competitive markets, and mitigate emissions. EnerNOC’s Utility Solutions™ offerings, which include both implementation and consulting services, are helping hundreds of utilities and grid operators worldwide meet their demand-side management objectives. EnerNOC serves thousands of commercial, institutional, and industrial customers worldwide through a suite of energy management applications including: DemandSMART™, comprehensive demand response; EfficiencySMART™, continuous energy savings; and SupplySMART™, energy price and risk management. EnerNOC’s Network Operations Center (NOC) offers 24x7x365 customer support. For more information, visit www.enernoc.com.

The EnerNOC, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5804

CONTACT: Media Relations: Robin Deliso,
         (617) 692.2601, news@enernoc.com
         Investor Relations: Brian Norris,
         (617) 532.8104, ir@enernoc.com
Friday, September 13th, 2013 Uncategorized Comments Off on (ENOC) VP Product Strategy and Tech Makes Boston Business Journal 40 Under 40

(CHFC) Announces Pricing of $50M Public Offering

MIDLAND, Mich., Sept. 13, 2013 — Chemical Financial Corporation (Nasdaq:CHFC) announced today the pricing of an underwritten public offering of 1,925,000 shares of its common stock at a price of $26.00 per share to the public. The Company has granted the underwriters a 30-day option to purchase up to an additional 288,750 shares of common stock sold to cover over-allotments. The public offering is expected to close on September 18, 2013.

The Company intends to use the net proceeds from this offering for general corporate purposes, which may include funding loan growth and long-term strategic opportunities that may arise in the future.

Keefe, Bruyette & Woods, a Stifel company, is the sole book-running manager in this offering. Raymond James & Associates and Sandler O’Neill + Partners, L.P. are acting as co-managers for the offering. Donnelly, Penman & Partners is acting as a selling group member.

The offering will be made under the Company’s shelf registration statement filed with the Securities and Exchange Commission (SEC) on May 23, 2013 and declared effective on June 7, 2013.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

The offering may only be made by means of a prospectus and a related prospectus supplement, copies of which may be obtained by contacting Keefe, Bruyette & Woods, Inc., Attention: Equity Capital Markets, 787 Seventh Avenue, 4th Floor, New York, NY 10019, telephone (800) 966-1559. Copies of the prospectus and related prospectus supplement may also be obtained from the SEC’s website at: www.sec.gov.

About Chemical Financial Corporation

Chemical Financial Corporation is the second largest banking company headquartered and operating branch offices in Michigan. The Company operates through a single subsidiary bank, Chemical Bank, with 156 banking offices spread over 38 counties in the lower peninsula of Michigan. At June 30, 2013, the Company had total assets of $5.8 billion. Chemical Financial Corporation’s common stock trades on The NASDAQ Stock Market under the symbol CHFC and is one of the issues comprising The NASDAQ Global Select Market. More information about the Company is available by visiting the investor relations section of its website at www.chemicalbankmi.com.

Forward-Looking Statements

This news release contains various forward-looking statements. A discussion of various factors that could cause Chemical Financial Corporation’s actual results to differ materially from those expressed in such forward-looking statements is included in Chemical Financial Corporation’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2012, and Quarterly Report on Form 10-Q for the period ended June 30, 2013.

CONTACT: For further information:
         David B. Ramaker, CEO
         Lori A. Gwizdala, CFO
         989-839-5350
Friday, September 13th, 2013 Uncategorized Comments Off on (CHFC) Announces Pricing of $50M Public Offering

(PME) Announces Delivery of 20 Newly-built Fishing Vessels

FUZHOU, China, Sept. 13, 2013 — Pingtan Marine Enterprise Ltd. (Nasdaq: PME), (“Pingtan,” or the “Company”) an integrated marine services company in the People’s Republic of China (PRC), today announced the recent delivery of 20 newly-built fishing vessels, which were initially ordered by the Company in September 2012.  With the addition of these vessels and the recent acquisition of 46 vessels in June 2013, the Company’s total current fleet has increased to 106.  The Company expects these vessels will materially increase its fish harvest volume and revenue, while being immediately accretive to net income.

The vessels delivered to the Company (full list below), which were built in Shandong Province, were delivered to the Company in early September.  These vessels have an expected run-in period of 3 – 6 months, in which each are placed into the sea for testing prior to full operation. At full operation, each vessel is capable of harvesting 900 to 1000 tons of approximately 30 types of species of fish from the Indian Ocean.  At current prices and operating at full capacity, each vessel can generate annual revenue of approximate $3 million USD with annual net income of approximate $800,000 to $1 million.

Mr. Xinrong Zhou, Pingtan’s Chairman and CEO, stated, “We are pleased to announce the delivery of these new vessels.  We believe that the expansion of our fleet will continue to create economies of scale for Pingtan.  Increasing our volume will help in our negotiations with distributors and exporters, and also create the possibility of selling downstream directly to end markets.  We expect to remain aggressive in increasing our fleet, and look forward to enhancing our leading position in China’s seafood industry.”

 

 

About Pingtan

Pingtan is a marine enterprises group, engaging in dredging services and ocean fishing through its wholly-owned subsidiaries, China Dredging Group and Merchant Supreme, and their respective PRC operating subsidiaries, Fujian Xinggang Port Service Co., Ltd., or Fujian Service, Pingtan Xingyi Port Service Co., Ltd., or Pingtan Xingyi and Fujian Provincial Pingtan County Ocean Fishing Group Co., Ltd., or Pingtan Fishing.

Pingtan Fishing primarily engages in ocean fishing with many of its self-owned vessels operating within the Indian Exclusive Economic Zone and the Arafura Sea of Indonesia. Pingtan Fishing is a growing fishing company and provider of high quality seafood in the PRC.

List of 20 Newly-built Fishing Vessels
Trawlers Fishing Area Carrying Tonnage Capacity (KW)
FuYuanYu 171 India 156 1000
FuYuanYu 172 India 156 1000
FuYuanYu 173 India 156 1000
FuYuanYu 174 India 156 1000
FuYuanYu 175 India 156 1000
FuYuanYu 176 India 156 1000
FuYuanYu 177 Indonesia 156 1000
FuYuanYu 178 Indonesia 156 1000
FuYuanYu 179 Indonesia 156 1000
FuYuanYu 180 Indonesia 156 1000
FuYuanYu 181 Indonesia 156 1000
FuYuanYu 182 Indonesia 156 1000
FuYuanYu 183 Indonesia 156 1000
FuYuanYu 184 Indonesia 156 1000
FuYuanYu 185 Indonesia 156 1000
FuYuanYu 186 Indonesia 156 1000
FuYuanYu 187 Indonesia 156 1000
FuYuanYu 188 Indonesia 156 1000
FuYuanYu 189 Indonesia 156 1000
FuYuanYu 190 Indonesia 156 1000

Business Risks and Forward-Looking Statements

This press release may contain forward-looking statements that are subject to the safe harbors created under the Securities Act of 1933 and the Securities Exchange Act of 1934. Readers are cautioned that actual results could differ materially from those expressed in any forward-looking statements. In addition, please refer to the risk factors contained in Pingtan’s SEC filings available at www.sec.gov, including Pingtan’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Definitive Proxy Statement. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. Pingtan undertakes no obligation to update or revise any forward-looking statements for any reason.

 

CONTACT:
Roy Yu
Chief Financial Officer
Pingtan Marine Enterprise Ltd.
Tel: +86 591 87271753
ryu@ptmarine.net

 

INVESTOR RELATIONS:
The Equity Group Inc.
Adam Prior, Senior Vice President
(212) 836-9606
aprior@equityny.com

In China
Katherine Yao, Associate
86 10 6587 6435
kyao@equityny.com

Friday, September 13th, 2013 Uncategorized Comments Off on (PME) Announces Delivery of 20 Newly-built Fishing Vessels

(NEWS) Taps Securitization Market for $400 Million in Benchmark Transaction

Completes Seventh Loan Securitization

  • Upsized deal from $350 million to $400 million due to strong investor interest
  • Six classes of notes were placed with a number of domestic and foreign investors
  • Priced all notes at par to yield a weighted average spread of approximately Libor plus 221 bps
  • Achieved an advance rate of approximately 85%, placing approximately $339 million of notes rated AAA/Aaa through BBB-
  • Retained notes rated BB and B in addition to equity interests totaling approximately $61 million, or 15% of the capital structure

BOSTON, Sept. 13, 2013 — NewStar Financial Inc. (Nasdaq:NEWS), a specialized commercial finance company, announced today that it completed a $400 million term debt securitization known as NewStar Commercial Loan Funding 2013-1. All classes of notes were priced at par and the transaction was upsized from $350 million, reflecting broad participation among institutional investors.

NewStar Commercial Loan Funding 2013-1 is NewStar’s seventh securitization since inception and part of a programmatic approach to the company’s funding strategy. The notes offered through this CLO transaction are backed by a diversified portfolio of commercial loans originated by NewStar. The transaction was executed through a private offering via Rule 144A and Regulation S. Various classes of notes rated AAA/Aaa through BBB- totaling approximately $339 million were placed and NewStar retained BB and B rated notes in addition to the equity interests, which together represented 15% of the capital structure, or approximately $61 million. The deal was also structured with a variable funding note class, rated AAA, to provide valuable funding flexibility.

“Our ability to attract strong interest from significant new and repeat investors in this transaction underscores the strength of NewStar’s track record and the value of our direct origination platform. The quality of the execution also reinforces our access to the capital markets and ability to expand and diversify our investor base,” said NewStar CEO, Tim Conway. “Natixis did an outstanding job structuring and marketing the deal to drive the best execution.”

“The CLO market continues to provide attractive term financing for our balance sheet and this deal marked another important milestone for us,” said John Frishkopf, head of asset management and treasury at NewStar. “Due to the market’s strong receptivity, we were able to upsize the deal and price all tranches at par to achieve an attractive structure and all-in interest cost.”

NewStar Financial will serve as manager of the CLO, which has a three-year reinvestment period. The class A notes are rated by two rating agencies and classes B – G are rated by a single agency. All notes were priced at par with a weighted average yield of LIBOR plus 2.21%.

Natixis was placement agent and sole book runner.

This announcement is neither an offer to sell nor a solicitation of an offer to buy the notes.

The notes subject to the private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws.

About NewStar Financial, Inc.:

NewStar Financial (Nasdaq:NEWS) is a specialized commercial finance company focused on meeting the complex financing needs of companies and private investors in the middle markets. The Company specializes in providing a range of senior secured debt financing options to mid-sized companies to fund working capital, growth strategies, acquisitions and recapitalizations, as well as equipment purchases. NewStar originates loans and leases directly through teams of experienced, senior bankers and marketing officers organized around key industry and market segments. The Company targets ‘hold’ positions of up to $30 million and will selectively underwrite or arrange larger transactions for syndication to other lenders. NewStar is headquartered in Boston MA and has regional offices in Atlanta GA, Chicago IL, Dallas TX, Darien CT, Los Angeles CA, New York NY, Philadelphia PA, Portland OR, and San Francisco CA. Please visit our website at www.newstarfin.com for more detailed information.

CONTACT: Corporate Inquiries:
         NewStar Financial
         Robert K. Brown
         (617) 848-2558
Friday, September 13th, 2013 Uncategorized Comments Off on (NEWS) Taps Securitization Market for $400 Million in Benchmark Transaction

(CTIC) Announces Sale of Convertible Preferred Stock

SEATTLE, Sept. 13, 2013 – Cell Therapeutics, Inc. (“CTI”) (Nasdaq and MTA: CTIC) today announced that it has agreed to sell 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the “Offering”).  The net proceeds from the Offering, after deducting estimated offering expenses, will be approximately $14.8 million.

Each share of Series 18 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time prior to the automatic conversion of such shares in certain circumstances, into a total of 15 million shares of registered common stock at a conversion price of $1.00 per share of common stock.  Shares of the Series 18 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock, but would be entitled to a liquidation preference over the common stock in certain liquidation events.  The Series 18 Preferred Stock will have no voting rights on general corporate matters.

CTI plans to use the net proceeds from the Offering to continue Phase 3 trials of pacritinib and to support the commercialization of PIXUVRI® (pixantrone) in Europe as well as for general corporate purposes, which may include, among other things, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications and general working capital.  The Offering is expected to close on or about September 18, 2013.

The securities described above are being offered by CTI pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”), which the SEC declared effective on November 1, 2011. A prospectus supplement related to the Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.  Alternatively, CTI will arrange to send you the prospectus supplement and the accompanying prospectus upon request by calling CTI at (206) 282-7100.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.  The shares of Series 18 Preferred Stock (and the shares of common stock into which each share of Series 18 Preferred Stock will be convertible) will not be offered, sold or distributed, directly or indirectly, in Italy in an offer to the public of financial products under the meaning of Article 1, paragraph 1, letter t) of Legislative Decree No. 58 of February 24, 1998, as amended (the “Financial Services Act”), unless an express exemption from compliance with the restrictions on offers to the public, including, without limitation, as provided under Article 100 of the Financial Services Act and Article 34-ter of CONSOB Regulation No. 11971 of May 14, 1999, as amended, applies.

About Cell Therapeutics, Inc.

CTI (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.  Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI’s securities.  Such statements include, but are not limited to, statements regarding CTI’s expectations with respect to the completion and timing of its proposed Offering and use of proceeds from the Offering.  Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks associated with market conditions and the satisfaction of customary closing conditions related to the proposed Offering; risks associated with the biopharmaceutical industry in general and with CTI and its product and product candidate portfolio in particular including, among others, risks associated with the following: that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that CTI cannot predict or guarantee the outcome of preclinical and clinical studies, that CTI may not obtain reimbursement for PIXUVRI in certain markets in the European Union as planned, that the conditional marketing authorization for PIXUVRI may not be renewed, that the second Phase 3 clinical trial of pacritinib will not occur as planned, that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities, that CTI may experience delays in the commencement of preclinical and clinical studies, risks related to the costs of developing, producing and selling PIXUVRI, pacritinib, and CTI’s other product candidates, and other risks, including, without limitation, competitive factors, technological developments, that CTI’s operating expenses continue to exceed its net revenues, that CTI may not be able to sustain its current cost controls or further reduce its operating expenses, that CTI may not achieve previously announced goals and objectives as or when projected, that CTI’s average net operating burn rate may increase, that CTI will continue to need to raise capital to fund its operating expenses, but may not be able to raise sufficient amounts to fund its continued operation as well as other risks listed or described from time to time in CTI’s most recent filings with the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K.  Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

PIXUVRI is a registered trademark of Cell Therapeutics, Inc.

Contacts:

Monique Greer
+1 206-272-4343
mgreer@ctiseattle.com

Ed Bell
+1 206-282-7100
ebell@ctiseattle.com

In Europe:

CTI Life Sciences Limited, Milan Branch
Laura Villa
E: lvilla@cti-lifesciences.com
T: +39 02 89659706
http://www.celltherapeutics.com/italiano

Friday, September 13th, 2013 Uncategorized Comments Off on (CTIC) Announces Sale of Convertible Preferred Stock
Top Small Cap Market News